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Chapter 1     
 
Introduction 
 
THE HISTORICAL BACKGROUND OF THE POLYMERASE CHAIN REACTION 
The Polymerase Chain Reaction (PCR) was pioneered by Kary B. Mullis, born in 1944 in 
Lenoir, North Carolina, USA [1]. Charged with making oligonucleotides for DNA 
sequence analysis, Mullis worked as a scientist for the Cetus Corporation of Emeryville, 
California. In 1983, whilst driving along a mountain road into northern California’s 
redwood country, Mullis was thinking about a means of determining the nucleotide 
present at a specific position of the beta-globin gene for diagnosis of sickle cell anaemia 
[2]. His thoughts were based on the techniques of dideoxy sequencing, a method first 
described by Sanger and Coulson in 1975 [2,3]. He then had a sudden intuition showing 
him a way of amplifying a DNA sequence in a single test tube [1,2]. Though we know 
today that the PCR uses multiple cycles at different temperature conditions to generate 
double-stranded DNA from a single-stranded DNA template (see ‘Basic principles of 
PCR’, page 6), Mullis was not certain during the early phase of his research that the 
reaction would not cycle itself. Assuming any chemical equilibrium to have some finite 
value, he believed that a portion of any nominally double-stranded DNA would be single-
stranded, meaning that single-stranded DNA templates would be permanently present 
during the amplification process [1,4]. Thus, the first Polymerase Chain Reaction, 
labelled ‘PCR01’ (see figure 1, page 6), was an isothermal process that did not lead to 
the expected DNA band on ethidium bromide stained agarose gel (see ‘Post-PCR 
Detection of Amplification Products’, page 9). It took Mullis and his colleagues from 
Cetus several months to achieve conditions producing convincing results [4]. Now 
familiar with exponential amplification of DNA sequences, they were able to present a 
method for the diagnosis of sickle cell anaemia starting from minimum amounts of 
genomic DNA [5].  
As PCR requires denaturation of double-stranded DNA through application of a high 
temperature to the reaction tube, a problem in the early phase of PCR was that the 
enzyme used for DNA amplification (the Klenow fragment of Escheria coli DNA 
polymerase) had to be replenished after each denaturation step [5,6]. This problem was 
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overcome by replacing the initially used enzyme with a heat stable protein isolated from 
an organism native in hot springs (Thermus aquaticus [Taq] DNA polymerase) [7,8,9].  
Kary B. Mullis was awarded the Nobel Prize in chemistry in 1993 for his discovery of the 
PCR method [10,11]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.: The first Polymerase Chain Reaction. Page from the notebook of Kary B. Mullis 
showing the reagents put together for ‘PCR01‘ in a purple-capped tube on September 8th, 1983 [4].  
 
BASIC PRINCIPLES OF PCR 
Various reaction components play a role in PCR. The DNA template sequence to be 
amplified can include purified DNA or RNA sequences converted to cDNA by reverse 
transcription [12,13]. A large molar excess of small pieces of synthetic single stranded 
DNA (so-called ‘primers’) determine the length and sequence of the amplification 
product [5]. The most frequently used thermostable polymerase is Taq DNA polymerase 
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[7,8]. Amplification reactions also include PCR buffer, deoxynucleotide triphosphates 
(dNTPs, an equal mixture of dATP, dTTP, dGTP and dCTP) and magnesium chloride 
(MgCl2) [7,9,14,15]. The sensitivity and specificity of a PCR reaction depend on the 
interaction of these reaction components, but the most important aspect is the primer 
design [16,17]. The ideal primer pair anneals to unique sequences that flank the target 
and not to other sequences in the sample [18]. A primer needs to be long enough to 
reduce the probability of the sequence being found at non-target sites. Typical primers 
are 18 to 24 nucleotides in length [5,6,19]. Despite some general desirable 
characteristics of primer sequences, the melting temperature (Tm) is another important 
parameter [20]. Tm is the temperature at which 50% of an oligonucleotide and its 
complementary sequence are present in a duplex DNA molecule [21]. Ideally, the 
annealing temperature of a primer is low enough to guarantee efficient annealing but 
high enough to minimise nonspecific binding [22]. Temperatures for primer annealing 
are initially set about 5°C below the Tm of the primers. Higher annealing temperatures 
are then tested to reduce the formation of any formed primer-dimers or nonspecific 
products [15]. 
The principle underlying PCR is shown in detail in figure 2 (page 8). In the first stage of 
the PCR reaction, double-stranded DNA molecules are separated at high temperature 
into their two component strands. The reaction tubes are then cooled down to a 
temperature that allows the primers to anneal at specific locations on the opposite 
strands of the target sequence. While the so-called “forward” (or “sense”) primers anneal 
to the anti-sense strands of the separated DNA template, the “reverse” (or “anti-sense”) 
primers anneal to the sense strand downstream from the sequence chosen for the 
forward primers. Taq DNA polymerases then "extend" the primers by attaching a 
complementary nucleotide to each nucleotide in the template strand. In this manner, the 
polymerase creates two identical double-stranded DNA helices from the two separated 
single strands of the original template molecule. The cycle of denaturation, primer 
annealing and strand synthesis is then repeated several times. As the products from one 
round serve as a template for the next amplification cycle, each additional cycle 
theoretically doubles the amount of accumulated PCR products [2,5,6,19].  
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Figure 2. Basic principle of PCR. First, double stranded DNA sequences are separated into single 
strands by applying high temperatures (usually 95°C) to the reaction tubes. 2. During the subsequent 
annealing step at an optimised temperature, the forward and reverse primers hybridise to their target 
sequences located on the opposite strands of the target DNA molecule. 3. Taking the resulting 
primer:template duplexes as a starting point, Taq DNA polymerases then synthesise a 
complementary strand to the single-stranded DNA matrices. The process of strand separation, primer 
annealing and extension is then performed repeatedly, resulting in the production of a large number 
of identical DNA strands. Since amplified products from the previous cycle serve as a template for 
the next amplification cycle, PCR is an exponential process and a highly sensitive technique for 
nucleic acid detection. 
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KINETICS OF PCR REACTIONS 
The amplification of nucleic acids is an exponential process that can be described by the 
equation 
 
P = I * (1+E)n 
 
where P is the copy number of accumulated PCR product, I is the initial copy number of 
the nucleic acid template of interest, E is the efficiency of the PCR reaction and n is the 
number of performed amplification cycles [5,23].    
The efficiency of a PCR reaction can vary from 0 (no amplification) to 1 (optimal 
amplification) [24] and depends on various parameters like the characteristics of the 
designed primer pair, the purity of the nucleic acid template, the performance of the Taq 
DNA polymerase used for amplification, and the length and the base composition of the 
PCR product [23,25-27]. Furthermore, the efficiency of the reaction depends on the 
distribution between the amplification product and the residual amount of free primers 
and dNTPs and the competition of amplification products for DNA polymerase binding 
[23,25]. Thus, the reaction trajectory at later stages of amplification diverges from an 
exponential to a stochastic type, resulting in a plateau phase at the end of the PCR 
reaction (see figure 3, page 11) [23,25,26].   
 
POST-PCR DETECTION OF AMPLIFICATION PRODUCTS 
Gel electrophoresis  
Electrophoresis through agarose or polyacrylamide gels is a standard method used to 
separate and identify PCR products directly after the amplification process or after 
additionally performed post-PCR modifications such as cleavage by endonucleases for 
restriction site analysis [19]. Because of their negative charge, nucleic acids become 
oriented in an electric field [28,29]. While moving to the positive electrode, molecules of 
double-stranded DNA migrate through gel matrices at rates that are inversely 
proportional to the log10 of the number of base pairs [30]. Small molecules migrate faster 
because of lower frictional drag and because they worm their way through the pores of 
the gel more efficiently than larger molecules [19]. The location of DNA within the gel 
can be determined directly by staining with low concentrations of a DNA-binding 
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fluorogenic molecule. The most commonly used fluorescent dyes are ethidium bromide 
and SYBR® green I. These fluorescent dyes intercalate between single bases of DNA. 
Because the fluorescent yield of dye:DNA complexes is much greater than that of the 
unbound dye, small amounts of DNA can be detected by exposing a stained gel to 
ultraviolet light [19,31]. Through gel electrophoresis, PCR products or DNA fragments 
resulting from downstream applications of PCR can be assigned after staining according 
to the corresponding number of base pairs. The application of polyacrylamide gels even 
permits a distinction between DNA fragments that differ by only one base-pair in length 
[32,33].  
 
Hybridisation techniques 
Although the length of a DNA fragment is an important parameter in the assessment of 
the specificity of an amplification process, no information about the base composition of 
a PCR product can be given by gel electrophoresis alone. Thus, it is often desirable to 
perform an additional oligonucleotide probe hybridisation step to obtain specific product 
discrimination without the need for DNA sequencing or restriction site analysis. A 
method to detect DNA fragments by specific hybridisation after gel electrophoresis was 
described by Southern as early as 1975 [34]. Nowadays, a large number of 
modifications of this method are used to assess DNA fragments usually resulting from 
PCR reactions. For example, the presence of particular mutations or polymorphisms can 
be determined by differential hybridisation with sequence-specific oligonucleotide probes 
[35,36]. Furthermore, compared to fluorescent dye stained gels, optimised hybridisation 
assays allow more sensitive detection of PCR products [37]. This aspect is particularly 
important for test systems established for the detection of infectious agents [37,38].  
 
IN-PROCESS DETECTION OF PCR PRODUCTS (REAL-TIME PCR) 
The combination of PCR and subsequent detection of amplification products has been 
described for a wide variety of applications [5,18,31,32,35-41]. However, all of these 
approaches require time-intensive post-PCR handling steps and bear the risk of reaction 
mixtures being contaminated by previously handled amplification products [42,43,44]. 
The development of various methods for the detection of PCR products during 
amplification in a closed-tube format (so-called ‘real-time’ PCR) solved these problems 
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and provided a means of gaining insight even into the early exponential phase of the 
amplification process [45]. 
 
Basic principles of real-time PCR  
Real-time PCR is based on continuous quantification of specific fluorescent reporter 
emission signals during the amplification process. The signal increases in direct 
proportion to the amount of PCR product accumulated in the reaction mixture [45,46,47]. 
By detecting the amount of fluorescence emission at each amplification cycle, it is 
possible to monitor the entire kinetics of an ongoing PCR reaction (see figure 3). 
 
Figure 3. PCR kinetics. Amplification curves of a 5’ nuclease assay performed on the ABI Prism® 
7700 SDS, showing fluorescence observations from the amplification of a 10-fold dilution series of 
tissue factor-cDNA after reverse transcription of corresponding mRNA templates. The 40 
observations of relative change in fluorescence intensity show the typical sigmoid trajectories of the 
amplification reactions from an exponential phase to a late plateau phase. Early amplification cannot 
be viewed, as the specific fluorescence signals from the used reporter dye cannot be distinguished 
from the background signal. The point at which amplification-derived fluorescence generation 
becomes significantly detectable is called the threshold cycle (Ct). While higher concentrations of 
starting templates result in a lower Ct value, lower concentrations produce higher Ct values. Under 
ideal conditions, a log10 difference in the starting concentration of the template DNA results in a 3.32 
cycle difference in the Ct value. 
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Platforms available for real-time PCR 
Nowadays, various real-time PCR systems using different chemistries for amplification-
dependent fluorescence generation are commercially available. Adapted thermal cyclers 
enable irradiation of the reaction mixtures and detection of emitted fluorescence signals 
by either a computer-controlled CCD camera or photodetection diodes [45,48,49]. Due 
to the parallel development of different real-time PCR platforms, the absorption and 
emission characteristics of the used fluorophores depend on the limitations given by the 
corresponding irradiation and detection system. At present the most commonly used 
platforms are the ABI Prism® 7000 series sequence detection system (SDS, Perkin 
Elmer Corporation/Applied Biosystems, USA) and the LightCycler™ instrument (Roche 
Molecular Biochemicals, Germany) [46,50,51]. 
 
Chemistries used in real-time PCR 
Real-time PCR has been made possible by the labelling of internal hybridisation probes, 
primers or the amplification product itself with fluorogenic molecules. The different 
methods can be classified into sequence-specific or non-specific methods.  
 
DNA-binding fluorophores  
The basis of the non-specific detection methods is the use of DNA-binding fluorogenic 
molecules. Higuchi et al. (1992) pioneered the possibility to monitor the accumulation of 
PCR products during the amplification process by including ethidium bromide directly 
into the reaction mixture. Ongoing amplification produced increasing amounts of double-
stranded DNA, resulting in an increase in fluorescence after each cycle of the PCR 
reaction [45]. However, non-specific real-time reactions performed nowadays usually 
contain the free intercalating dye SYBR® Green I [47,48]. The advantages of SYBR® 
Green I assays is that they are inexpensive and easy to use. The disadvantage is that 
SYBR® Green I will bind to any double-stranded DNA in the reaction, including primer-
dimers and non-specific reaction products [48,52].   
 
Fluorogenic hybridisation probes 
Holland et al. (1991) first described the possibility of incorporating sequence-specific 
product discrimination by probe hybridisation directly into the PCR process. Their 
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method was based on a γ-32P-labelled probe designed to hybridise within the target 
sequence chosen for amplification. The probes also contained a 3’ phosphate moiety, 
which blocked their extension by the used polymerase. Annealing of the probe to one of 
the PCR product strands generated a suitable substrate for the 5’-3’ exonuclease activity 
of Taq DNA polymerase [53]. Thus, annealed probes were degraded during 
amplification into smaller fragments that could be differentiated from intact probes by 
radiography performed after thin-layer chromatography [54]. Numerous modifications of 
this initially described 5’-exonuclease assay led to the development of various 
fluorogenic hybridisation probes used for specific product detection during the 
amplification process of the PCR. 
Internal fluorogenic oligonucleotide probes provide an additional hybridisation step that 
improves the specificity of the test system and allows specific product discrimination. 
Different fluorophores with emission profiles peaking at different wavelengths can be 
used to perform multiplex real-time PCR assays that allow parallel detection of multiple 
amplification products in the same reaction mixture [55,56]. For details see below and 
figure 4 on page 15. 
 
5’ Nuclease probes 
5’ nuclease probes (also called hydrolysis or TaqMan® probes) are based directly on the 
principle of the 5’-exonuclease assay described by Holland et al. in 1991 [54]. These 
probes contain a fluorescent dye on the 5' base and a quenching dye typically on the 3' 
base [57]. When irradiated, the excited fluorescent dye transfers energy to the nearby 
quenching dye molecule by fluorescence (or Förster) resonance energy transfer (FRET) 
[58,59]. Thus, the close proximity of the reporter dye and the quencher prevents 
emission of fluorescence specific for the used reporter dye [46,57]. Probe degradation 
by the 5’-3’ exonuclease activity of Taq DNA polymerase ends this quenching effect and 
the reporter dye starts to emit fluorescence at an expected wavelength [60,61]. To date, 
the 5’ exonuclease assay (also called TaqMan® assay) has been the main application 
performed on the ABI Prism® 7000 series real-time PCR platform [46].  
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Adjacent hybridisation probes 
In a reverse process to the quenching effect described above, a pair of adjacent, 
fluorogenic hybridisation probes can also be used for homogenous product detection by 
FRET [62]. An upstream probe is 3’-labelled with a donor fluorophore while a 
corresponding downstream probe is 5’-labelled with an acceptor fluorophore. After 
irradiation, a signal from the acceptor can only be generated when the donor comes into 
close proximity to the acceptor after adjacent probe hybridisation during the annealing 
phase of the PCR reaction [63]. This system, also known as the ‘HybProbes’ system, 
has become the method of choice for the LightCycler™ instrument [51].  
 
Hairpin probes 
Another principle of specific homogenous product detection is the use of molecular 
beacons or Scorpion primers.  
Molecular beacons contain a fluorescent and a quenching dye at either end but they are 
designed to adopt a hairpin structure while free in solution to bring the fluorescent dye 
and the quencher in close proximity [64]. This results in quenching either by FRET or 
direct energy transfer by collision mechanisms [65,66]. When the molecular beacon 
hybridises to the target during the annealing step, the reporter dye is separated from the 
quencher and the reporter fluoresces [64,67].  
Scorpion primers combine a hairpin structure described above with one of the primer 
sequences. After annealing of the primer section, the hairpin structure of the probe 
section is only disrupted by specific hybridisation of the probe sequence downstream 
from the nascent strand [68,69].   
Generally, hairpin structures provide a stable alternative to the binding of the probe 
sequence to a single-stranded DNA target. Thus, hairpin oligoprobes are a sensitive tool 
for single nucleotide polymorphism (SNPs) analysis [64,70,71].    
 
Light-up probes 
Light-up probes consist of a peptide nucleic acid (PNA) to which an asymmetric cyanine 
dye (usually thiazole orange) is attached. Upon probe hybridisation, thiazole orange 
binds to the target DNA and becomes strongly fluorescent [72,73]. Using a single 
reporter dye permits fluorescence to be detected directly instead of the change in the 
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fluorescence intensity distribution between two fluorophores having to be measured 
when FRET is performed. Thus, light-up probes combine the advantage of a non-
specific intercalating dye with sequence-specific hybridisation [72,73,74]. 
 
Figure 4. Different chemistries of fluorogenic hybridisation probes. Upper left: 5’ nuclease 
probes. Downstream from one of the amplification primers a dual-labelled hybridisation probe also 
anneals to one of the single strands of the DNA target molecule present after the denaturation step. 
During primer extension the 5’-3’ exonuclease activity of the Taq DNA polymerase hydrolyses the 
probe, separating the reporter dye ({) from the quencher (z), giving rise to specific fluorescence 
emission. Upper right: Scorpion primers. After annealing, the primer section is extended by the 
Taq DNA polymerase. After strand separation, the probe section of the Scorpion oligonucleotide 
hybridises to a region downstream from the primer sequence during the next annealing step of the 
PCR reaction. The hairpin structure of the Scorpion primer is blocked from extension (®) by opposite 
strand synthesis to ensure that reporter dye ({) and quencher (z) are only separated by specific 
hybridisation of the probe section to the target sequence. Lower left: Adjacent hybridisation 
probes. Two linear fluorogenic oligoprobes hybridise next to each other to the target sequence 
during the annealing step of the PCR reaction. The acceptor dye (z) then emits fluorescence due to 
FRET resulting from the interaction with the donor dye ({) in close proximity. Lower right: 
Molecular beacons. Hybridisation of the probe sequence to the target sequence during the 
annealing step separates the reporter dye ({) from the quencher (z). 
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Fluorogenic primers 
In contrast to fluorogenic oligonucleotide probes, a fluorogenic primer system does not 
further improve the specificity of a real-time PCR reaction, as an additional probe 
hybridisation step is not performed. Thus, any primer-dimers or non-specific reaction 
products formed may interfere with expected test results. However, the use of different 
reporter dyes also permits multiplex reactions and allelic discrimination approaches. 
Although various strategies for self-reporting primer systems have been described in the 
literature [75,76,77], only two of these systems, the Sunrise primers (also called 
Amplifluor™ hairpin primers) and the LUX™ primers, seem to ensure satisfactory results 
and are therefore commercially available. See also figure 5 (page 17). 
 
Sunrise Primers 
Like Scorpion primers, the so-called Sunrise (or Amplifluor™) primers combine a hairpin 
structure (which provides quenching of a reporter dye) with one of the primer 
sequences. In contrast to Scorpion primers, the hairpin structure of Sunrise primers is 
intended to be duplicated by opposing strand synthesis and is therefore incorporated 
into the PCR product, keeping the quencher and the reporter dye apart [76,78].  
 
LUX™ Primers 
The so-called LUX™ (Light Upon Extension) system includes a primer with a single 
fluorophore attached to its 3’ end. The fluorogenic primer also provides a short 
sequence at its 5’ end that is complementary to the 3’ end. The resulting hairpin 
structure ensures quenching of the reporter dye by an adjacent guanine base. However, 
when the primer is incorporated into the PCR product, the signal of the reporter dye 
increases up to 10-fold [77,79]. In addition to having the disadvantages of fluorogenic 
primers described above, this real-time PCR system is restricted to specific sequence 
characteristics of the target DNA required for successful primer design [80]. 
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Figure 5. Fluorogenic primer 
chemistries. Top: Sunrise 
primers. Strand synthesis takes 
place after annealing of the 
primer section of the Sunrise 
primer to the target sequence. 
During duplication of the opposite 
strand, the hairpin structure of the 
Sunrise primer is incorporated 
into the PCR product. This 
separates the reporter dye ({) 
from the quencher (z), giving rise 
to specific fluorescence emission. 
Bottom: LUX™ Primers. In the 
hairpin structure, the reporter dye 
({) is sufficiently quenched by a 
guanine base in close proximity 
on the same strand. After 
incorporation of the LUX™ primer 
into the PCR product this 
quenching effect decreases, 
giving rise to increased 
fluorescence emission. 
 
COMMON APPLICATIONS OF REAL-TIME PCR 
The most common applications of real-time PCR are quantitative detection of nucleic 
acids (mostly mRNA converted to cDNA) in biological samples and discrimination 
between different sequences of amplification products [56,63,64,69,70,81]. The 
advantages over conventional PCR assays are that real-time PCR eliminates the need 
for post-PCR processing and therefore helps to increase throughput, reduces the 
chances of carryover contamination, allows multiplex reactions and removes potential 
errors resulting from post-PCR processing [45,46]. Regarding exclusively the 
quantification of nucleic acids, real-time PCR ensures reliable results from the analysis 
of single reaction set-ups and offers a broad dynamic range of at least 5 orders of 
magnitude, eliminating the need for prior sample dilution [46,82,83].  
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Quantification of nucleic acid templates 
As described above, the number of PCR products accumulated after a specific number 
of amplification cycles in a PCR reaction depends directly on the initial copy number of 
the nucleic acid template to be amplified. However, a log-linear relationship between 
these parameters is only given in the exponential phase of the PCR reaction, where the 
amount of accumulated amplification products does not yet have a negative influence on 
the efficiency of amplification [23,26]. Prior to the introduction of real-time PCR assays in 
1992, quantification of nucleic acids was based exclusively on the quantification of 
amplification products in post-PCR procedures. The most common and reproducible 
technique for performing quantitative PCR in a conventional ’endpoint’ format is the 
competitive PCR method that has been used for a variety of applications [84-87]. 
However, this method is labour-intensive and requires results from multiple reactions for 
each sample to be analysed [83,88]. Moreover, PCR reactions have to be stopped in the 
exponential amplification phase to enable reliable quantification of target sequences. 
This prerequisite limits endpoint quantification assays with regard to their sensitivity and 
dynamic range [82,83].  
Real-time PCR has overcome these limitations, as the entire kinetics of different PCR 
reactions can be monitored [45]. Even during the exponential phase of amplification, the 
fluorescence signals rise higher than the unspecific background. This specific point is 
called crossing point (CP) or threshold cycle (Ct) and represents the parameter used for 
quantification in real-time PCR assays (see figure 3, page 11).  
Absolute quantification requires an absolute calibrator to determine the number of initial 
nucleic acid targets in the sample reactions [47,83]. A log-linear interpolation between 
initial copy numbers of the calibration curve and the corresponding Ct values observed is 
then used for calculation of the initial copy numbers present in the unknowns (see 
chapter 2, figure 2).  
Relative quantification is most commonly used in gene expression analysis and is based 
on the relative expression of a target gene compared to a reference gene [89]. Two 
methods used for relative quantification purposes have been described: the calibration 
curve method and the comparative Ct value method [90]. In the calibration curve method 
the input amounts of both the target and the reference gene transcripts are calculated 
from individual calibration curves (see chapter 3). This approach is the method of choice 
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if the efficiencies of the different amplification systems are either unknown or unequal. 
Use of the comparative Ct value method (also called ddCt method) is subject to the 
prerequisite that the amplification efficiencies of the target and reference transcripts are 
approximately equal and close to 1. If these requirements are fulfilled, relative 
expression patterns of the target transcript in different samples can be derived direct 
from the corresponding differences of the Ct values obtained from amplification of target 
and reference transcripts [90,91]. Basically, all chemistries described for use in real-time 
PCR applications can be applied for quantitative detection of nucleic acids as described 
above. Nevertheless, only the use of fluorescence-labelled oligonucleotides offers the 
possibility to apply multiplex reactions in order to detect both the target and a possible 
reference template in a single amplification reaction [77,92,93,94]  
 
Sequence-specific discrimination 
Discrimination between different target sequences in a multiplex single reaction set-up 
by internal fluorescence-labelled oligonucleotide probes was first applied by Lee et al. 
[56]. Although the 5’ nuclease principle was used in this initially described assay, all 
probe or primer chemistries described above can theoretically be adapted to sequence-
specific discrimination approaches. To date, applications for sequence-specific 
discrimination have been used primarily for allelic discrimination of single nucleotide 
polymorphisms (SNPs) in human genes. Two basic methods are currently performed for 
single-tube genotyping: multicolour applications and melting curve analysis.  
At present, the multicolour method is performed mainly with 5’ nuclease probes or 
molecular beacons [64,70,95]. Generally, a pair of different fluorescence-labelled allele-
specific hybridisation probes is added to the reaction mixture. During the annealing 
phase of the amplification reaction the probes hybridise perfectly only to their 
complementary target sequences, giving rise to a fluorogenic emission spectrum that is 
specific for the corresponding genotype. During amplification the reporter signals further 
increase to a level that enables allelic discrimination by end-point measurements of 
specific fluorescence intensities (see figure 6, page 20) [56,67,95].  
Melting curve analysis is adapted primarily to the LightCycler™ instrument with a pair of 
adjacent oligoprobes. On completion of amplification, the reaction is cooled to a 
temperature ensuring hybridisation of both the donor and the acceptor probe. During 
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subsequent heating of the reaction mixture according to a time-dependent temperature 
ramp, the emission profile of the acceptor dye is constantly monitored. Software is then 
used to calculate the first derivative of the measured fluorescence over time, showing 
clear peaks representing the Tm of the probe-target hybrid. Even if a single base-pair 
substitution meets the target sequence of one of the two probes, the Tm is shifted to a 
lower temperature and this very shift can be used for genotyping purposes [96,97,98]. 
 
Figure 6. Main principles of allelic discrimination using fluorogenic hybridisation probes. Left: 
5’ nuclease probes. Two differently labelled allele specific hydrolysis probes compete for 
corresponding target sequences present in the DNA sample. During the extension of the target 
strand, only perfectly matched probes are hydrolysed by the 5’-3’ exonuclease activity of the Taq 
DNA polymerase while mismatched probes are only put aside and remain intact. Right: Molecular 
beacons. Two differently labelled molecular beacons compete for corresponding target sequences. 
Due to competition between the stem and the target sequence, only perfectly matching target 
sequences lead to disruption of the hairpin structure, giving rise to fluorescence.     
 
PCR APPLICATIONS IN HAEMOSTASIS AND TRANSFUSION MEDICINE 
The general introduction of PCR into the medical field broadened the possibilities of both 
diagnostics and research substantially. In transfusion medicine, PCR has been used for 
the screening of blood products for viral nucleic acids and the genotyping of transfusion-
relevant antigen systems. In the field of haemostasis, PCR has become a powerful tool 
in the diagnosis of genetically determined risk factors associated with either thrombosis 
or bleeding disorders. In general, the advent of real-time PCR increased the throughput 
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in routine diagnostics and improved the research potential in the field of haemostasis 
and transfusion medicine. 
 
Viral safety of blood products  
In 1999, nucleic acid amplification testing (NAT) for the screening of blood donations for 
genomes of the hepatitis C virus (HCV) was made mandatory by the Paul-Ehrlich-
Institute, the German regulatory authority for transfusion medicine [99]. This step was 
justified by the fact that the long-lasting preseroconversion phase of HCV infection leads 
to a diagnostic window period of up to 70 days if donations are tested exclusively for 
antibodies against HCV. This window period is reduced by 41-60 days if blood donations 
are additionally tested by NAT [100].  
In the case of human immunodeficiency virus (HIV) infection, antibodies become 
undetectable before 22 days on average. The use of NAT for HIV-RNA has the potential 
to reduce the window period to 10-15 days [100]. As a consequence, the screening of 
blood donors for HIV-1 group M genomes became mandatory in Germany from May 1, 
2004 [101].  
With obligatory NAT testing the residual risk of unrevealed HCV or HIV-1 window period 
donations is now estimated to be less than 1 in 5,000,000 [102].  
A variety of procedures is available for the detection of viral RNA in blood donations. 
Among the different techniques used for NAT, reverse transcriptase polymerase chain 
reaction (RT-PCR) is the most common used [50,69,81,85,103,104]. Protocols applying 
isothermal methods like nucleic acid sequence-based amplification (NASBA) and the 
very similar transcription-mediated amplification (TMA) have also been described 
[105,106,107].   
Regarding the screening of blood donations for viral DNA, the principle underlying PCR 
is without an applicable alternative [108]. However, obligatory viral DNA screening of 
blood donations used for the production of single therapeutic units is not yet scheduled 
in Germany but is hotly debated in the case of the hepatitis B virus (HBV) [109,110].  
Viral safety aspects are of equal or much greater importance in the industrial production 
of coagulation factor concentrates, e.g. factor VIII, factor IX, PPSB or FEIBA, that are 
manufactured from plasma pools containing thousands of single donations. Thus, single 
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plasma units destined for use in production pools should routinely be tested for hepatitis 
A virus (HAV), HBV, HCV, HIV-1 and parvovirus B19 genomes [111,112].   
The high sensitivity of NAT assays allows the strategy of pool testing [100]. Potentially 
present viral nucleic acids are either directly isolated from a pool of single donations or, 
in order to enhance sensitivity, from a corresponding ultracentrifugal pellet [113,114].The 
isolated nucleic acids then serve as a template in subsequently performed NAT assays 
[115]. 
A variety of methods may be used to detect an amplified viral sequence. The screening 
of blood donations by real-time PCR assays even allows reliable quantification of the 
viral load in positive samples [81,116,117,118]. This is of special importance if plasma 
donations used for production pools are to be tested for parvovirus B19 DNA (see 
Chapter 2). Another advantage of real-time PCR applications is the use of an internal 
inhibition control to monitor the efficiency of the amplification process [103,108]. This 
feature designed to avoid false negative test results is made possible by the multiplex 
configuration of real-time PCR assays. 
 
Diagnosis of genetic determinants 
PCR diagnostics simplified the genotyping of several phenotypic variants proving to be 
of importance in transfusion medicine substantially. For example, the development of 
corresponding PCR assays allow the genetic determination of the AB0, rhesus or Kell 
blood groups [119,120,121]. Furthermore, genotyping of human leukocyte antigens 
(HLA) or human platelet antigens (HPA) by PCR approaches enhanced the scope of 
currently applied transfusion medicine [122,123,124].    
In the field of haemostasis, a variety of specific polymorphisms or mutations have been 
identified to be genetic risk factors for either venous or arterial thrombosis. The most 
frequently discussed allelic variants are located within the genes coding for plasmatic 
coagulation factors or platelet surface antigens [125 -129]. To date, however, routine 
diagnostics for genetic thrombophilic risk factors is restricted mainly to the factor V 
Leiden mutation and the prothrombin G20210A polymorphism [125,127]. The most 
common methods used for determining these variants are the amplification of the target 
region followed by restriction site analysis (RFLP) or the use of sequence specific 
primers (SSP) [130 - 132]. In order to enable a higher throughput of patient samples 
23 
without the need for time-consuming post-PCR steps, several real-time PCR 
applications for the detection of these as well as of several other thrombosis-associated 
polymorphisms/mutations have been developed [95,97,133,134].       
Hereditary bleeding disorders are mainly associated with mutations located in the genes 
of coagulation factors VIII or IX, causing haemophilia of type A or B, respectively 
[135,136]. A variety of point mutations, deletions or inversions in these genes have 
already been described [137 - 140]. It was only the implementation of PCR that enabled 
the individual genetic variant in the genes of either factor VIII or IX in haemophiliac 
patients to be identified, e.g. by heteroduplex analysis in an acceptable time window 
[141,142]. 
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AIM OF THE THESIS 
The aim of the present thesis was the application of novel real-time PCR approaches 
into the haemotherapeutic field. The ABI Prism® 7700 sequence detection system 
platform was used for the development of 5’ nuclease assays applied for diagnostics 
and research in haemotherapy. 
 
- Chapter 2 describes the development of a fully validated 5’ nuclease assay for 
the screening of blood donations for parvovirus B19 DNA. 
 
- An evaluated 5’ nuclease assay for the quantification of tissue factor (TF) mRNA 
in circulating blood monocytes is presented in Chapter 3. 
 
- A study described in Chapter 4 shows the potential of 1-deamino-8-d-arginine 
vasopressin (DDAVP) to upregulate TF gene expression in blood monocytes in 
vivo. TF mRNA levels in white blood cells were quantified using the method 
described in chapter 3 with modifications. 
 
- In order to evaluate a newly established method for global amplification of platelet 
mRNA sequences, a quantitative 5’ nuclease assay for the detection of von 
Willebrand factor (vWF) and GAPDH mRNA sequences in a multiplex 
configuration was developed (Chapter 5). 
 
- Chapter 6 describes a study on the prevalence of molecular thrombophilic risk 
factors in patients with dural arteriovenous fistulas (DAVFs). Several 
polymorphisms were detected by partially unpublished restriction site analyses or 
5’ nuclease assays. 
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SUMMARY 
BACKGROUND: Human parvovirus B 19 (B19) is a single-stranded and non-enveloped 
DNA virus. In the majority of patients infections with B19 are benign and characterised 
only by malaise and exanthema of the skin. In a small subset of patients B19 infections 
induce severe complications including aplastic anaemia, chronic affections of the joints 
and fetal injuries up to abortion during pregnancy. Since B19 is transmitted through 
contaminated blood donations, testing for B19 DNA is taken into consideration to further 
increase virus safety of blood products. MATERIAL AND METHODS: TaqMan 
technology, a homogenous and real-time fluorescence PCR approach, has been applied 
for identification of B19 DNA. Primers were designed that amplify a DNA fragment 
located within a conserved region of non-structural protein 1 (NS1). A B19 variant 
showing a 27 base-pair inversion was constructed to be used as internal control. The 
assay was validated according to the criteria of the European regulatory authorities. 
RESULTS: The assay had a sensitivity limit of 104 genome equivalents per ml. False-
negative results due to problems with amplification were ruled out by the use of an 
internal control DNA. Reliable quantification of B19 DNA was possible by the use of a 
standard curve. CONCLUSIONS: A real-time PCR procedure for B19 virus DNA 
detection that is based on the TaqMan-technology has been developed and validated. 
The procedure is applicable for routine testing of single blood donations as well as for 
analysing large scale plasma pools.  
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INTRODUCTION 
Human parvovirus B19 (B19) is a single-stranded DNA virus of the genus erythrovirus 
within the family of parvoviridae. The viral genome of 5.4 kb encodes two capsid 
proteins (VP1 and VP2) and the three non-structural proteins NS1, P11, P7.5 [1,2]. B19 
is an ubiquitous virus. By the age of 15, about 50% of individuals have serologic 
evidence of a past infection [3,4]. In immunologically component individuals the B19 
infection may be asymptomatic or cause the common childhood disease erythema 
infectiosum. The infection is cleared within several weeks by specific antibodies and 
cytotoxic T-cells [5]. However, even in the presence of neutralising antibodies circulating 
B19 viruses can be detected up to one year after infection [6]. In patients with absent or 
dysfunctional humoral immunity, persistent infection can occur, which induces chronic 
haematological disorders including chronic anaemia, neutropenia, and 
thrombocytopenia [7,8]. In addition, B19 infections in pregnancy are associated with a 
high risk for fetal injuries and spontaneous abortion [9].  
There are several reports that describe transmission of B19 through blood 
products [10,11,12]. Recent studies have shown that outside an epidemic period up to 1 
in 3,300 donations and within an epidemic period 1 in 167 donations may contain 
detectable B19 virus DNA [13]. To enhance transfusion safety, testing of blood donors 
for B19 should be taken into consideration, especially for recipients of blood products 
that are exceptionally at risk in case of B19 infection. Screening for IgM antibodies is not 
very reliable in order to identify viremic blood donors, as IgM antibodies do not emerge 
until 10 days after infection but an intense viraemia develops approximately after 5-8 
days [2,14]. Furthermore, IgM antibodies are still detectable several weeks after 
complete clearance of the B19-virus [15]. Thus, nucleic acid amplification techniques 
(NAT) are the most suitable method to identify B19 contaminated blood donations. 
The possibility of viral load quantification is an additional advantage of NAT 
screening. This is especially important for screening of plasma donations used for 
production pools. Donations containing high titers of B19 can be identified and removed 
from pooling, whereas donations containing low titers of B19 should not be discarded 
because of their desirable high content of protective antibodies against B19 [16]. 
This report details the development and validation of a quantitative PCR-assay 
based on real-time PCR using ABI Prism SDS7700 (TaqMan) for large-scale screening 
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of blood products for B19 DNA. TaqMan is a homogeneous fluorescence generation 
system that detects target DNA as the PCR proceeds in real time. It functions by 
including an oligonucleotide probe designed to hybridise downstream of one of the 
primers. These probes are blocked from extension at their 3´-terminus and are labelled 
with a fluorescent reporter at the 5´-terminus. The probes are also conjugated to another 
fluorophore, which quenches the fluorescence of the reporter when both labels are in 
close proximity. During PCR, the probe is cleaved by the 5´-exonuclease activity of DNA 
polymerase. This cleavage separates the fluorescent reporter dye from the quencher, 
giving rise to an increase in fluorescence [17,18]. The TaqMan technology measures the 
emission in each PCR cycle. The cycle at which the fluorescence rises higher than the 
background signal is called threshold cycle (Ct-value) and is proportional to the 
concentration of target DNA added to the PCR mixture.  
Especially in a blood bank setting inhibition of amplification must be reliably 
identified to prevent false-negative results. Reporter dyes showing different fluorescence 
emission characteristics are commercially available. Therefore, the TaqMan approach 
allows analysis of several amplicons simultaneously. This enables the construction and 
use of an internal standard that was used to monitor the efficiency of the amplification 
process. 
 
MATERIALS AND METHODS 
Extraction of viral DNA from plasma 
Viral DNA was isolated from 140µl plasma by spin column procedure using the viral 
RNA Mini Kit ® (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. 
This protocol does not separate RNA from DNA and can therefore be used for 
purification of DNA as well. After adding the lysis buffer, 50 copies of an internal control 
were added to each sample to evaluate both, extraction and amplification. Purified DNA 
was eluted in 50µl of water. 
 
B19-TaqMan-PCR-assay 
Primers and probes were designed using Primer Express Software ® Version 1.5 (PE 
Applied Biosystems, Foster City, USA). The primer set amplifies a 78 base pair fragment 
in a conserved NS1 region of B19. The primers used were 5’-AAGCC-
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ATTTTAGGCGGGC-3’ (forward) and 5’-CCACAGGTACTCCAGGCACAG-3’ (reverse). 
The wild type specific probe was 5’-CCCACCAGGGTAGATCAAAAAATG- CGT-3’, 
labelled with the fluorescent dye FAM (6-carboxyfluorescein) at the 5’ end and the 
quencher TAMRA (6-carboxytetramethylrhodamine) at the 3’ end. The internal control 
probe was 5’-TGCTAAAAAACTAGATGGGACCACCC-3’, labelled with the fluorescent 
dye VIC at the 5’ end and TAMRA at the 3’ end. Nucleotide homology compared to 
sequences other than Parvovirus B19 was checked for all oligonucleotides against 
EMBL, GenBank and DDBJ using the BLAST algorithm (www.ncbi.nlm.nih.gov/BLAST). 
Primers were purchased from Eurogentec (Seraing, Belgium), probes were obtained 
from PE Applied Biosystems  (Weiterstadt, Germany). 
Optimal amplification conditions in a final volume of 25 µl were found to be 1x PCR 
buffer (20mM Tris-HCl, pH 8.5, 50mM KCl), 7mM MgCl2 , 200µM dATP, dCTP and 
dGTP, 400µM dUTP, 300nM forward primer, 900nM reverse primer, 200nM wildtype- 
and internal control-probe, 0.5µl Rox reference dye, 1.25 U PlatinumTaq DNA 
Polymerase ®, 0.5U uracil-N-glycosylase and 10 µl of the sample preparation. 
PlatinumTaq DNA Polymerase ® and Rox reference dye were purchased from 
Invitrogen (Groningen, Netherlands). Thermal cycling was performed using the ABI 
Prism 7700 Sequence Detection System ® (PE Applied Biosystems). The following 
amplification profile was used: 50°C for 2 min, 95°C for 10 min followed by 45 cycles 
consisting of denaturation at 94°C for 20s and annealing and extension at 57°C for 1 
min.  
 
Internal and external controls 
For construction of an internal inhibition control, a synthetic 180 base pair 
oligonucleotide was used. The sequence of this internal control sequence is identical to 
the B19-DNA sequence ranging from nucleotide 1526 to nucleotide 1705 [19], thus 
including the segment being amplified by the B19 TaqMan-PCR with the only exception 
that the 27 bp spanning hybridisation area where the TaqMan probe anneals was 
inverted. The synthetic oligonucleotide was amplified by PCR. The primers used for 
amplification were 5’-CAGGGAAAAGCTTGGTGG-3’ (forward) and 5’-
CGCTTACAACAAAAGTAATGTCA-3’ (reverse). The control oligonucleotide and 
amplification primers were purchased from Eurogentec. After purification using the PCR 
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Purification Kit ® (Qiagen, Hilden, Germany), the amplification products were ligated in 
pGEM-T vectors (Promega,Woods Hollow Road, USA) and used as an internal control 
after purification from transformed TOP10 ® E.Coli culture (Invitrogen, Groningen, 
Netherlands). The concentration of the internal control was determined by photometric 
measurement of the purified plasmid-DNA. 
A quantification standard was prepared from B19 positive plasma, that was 
obtained from the National Institute for Biological Standards and Control (NIBSC, Potters 
Bar, Great Britain). This plasma contains 107 genome equivalents per ml (geq/ml) and 
represents a 1:10 dilution of a B19 DNA positive single donation that was used to 
prepare the NIBSC B19 DNA working reagent (Code 97/542) containing 1,000 geq/ml. 
Standard plasma was aliquoted and stored at –80°C until used. For construction of a 
standard curve, B19 DNA was extracted from standard plasma and serially diluted with 
water to achieve final concentrations ranging from 3 to 28.000 geq/PCR-reaction 
corresponding to 1 x 102 to 1 x 106 geq/ml.  
In addition, a run-control containing 250 geq/ml was prepared from standard 
plasma by diluting it with negative plasma and used as a positive control in every run.  
 
Reference samples 
Twelve Parvovirus B19 DNA positive samples were provided from the Institute of 
Medical Microbiology and Immunology, University of Bonn. All samples were previously 
tested for B19-DNA using a nested PCR assay [20]. 
 
Probit analysis on experimental data 
Probit analysis was performed using software (SSPS ®, Base-Line, Munich, Germany). 
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RESULTS 
Development of the B19 TaqMan PCR  
A single, correctly sized PCR product was found on an ethidiumbromide stained 2% 
agarose gel using the described primer combination. Real-time-PCR conditions were 
optimised in order to define an amplification protocol that combines a maximum of 
sensitivity with stable reproducibility. Parameters evaluated include the concentrations of 
primers and probes and the MgCl2 concentration of the PCR reaction mix. For 
optimisation of primer concentrations, both primers were tested in a primer matrix at 
concentrations ranging from 50 nM to 900 nM. Optimal results were obtained at 
concentrations of 300 nM and 900 nM for the forward and reverse primer, respectively. 
Magnesium chloride concentrations ranging from 2 to 10 mM were studied. The highest 
fluorescence intensity was obtained at a MgCl2 concentration of 7 mM. Varying the 
concentrations of the hybridisation probes (50 – 300nM), the highest level of 
fluorescence generation was seen at concentrations ranging from 200 to 300 nM for 
both probes. Therefore, a concentration of 200 nM was defined as the working 
concentration used for both probes.  
Amplification of the internal control showed a single band that was identical in 
size to the 78 bp B19-wildtype-PCR product. In a second series of experiments, the 
internal control was serially diluted to establish the optimal working concentration, found 
to be 50 copies/extraction. Based on these results 50 copies of the internal control were 
added in the extraction-step in all further experiments. A possible influence of the 
internal control on the sensitivity of the B19-TaqMan-PCR was assessed by B19 DNA 
amplification (1,000 geq per ml of the plasma sample) in the presence and absence of 
50 copies of the internal control. Identical amplification efficacies ruled out an 
interference of the control reaction with the B19 DNA amplification (data not shown). 
 
Specificity and sensitivity of the B19 PCR 
Theoretically, unspecific results using the TaqMan-technology are very unlikely justified 
by the fact that in addition to the primer-pair the fluorescent-labelled probe has to bind to 
the template DNA as well in order to achieve a positive fluorescence signal. In order to 
confirm the specificity of the B19 TaqMan PCR, plasma samples from 100 blood donors 
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were analysed. In none of the 100 plasma samples a specific amplification signal was 
obtained using a total of 45 cycles in the TaqMan-PCR.  
The detection limit of the B19-TaqMan-PCR was evaluated using B19 positive standard 
plasma showing a concentration of 107 geq/ml. Pre-diluted standard plasma was 2-fold 
diluted using B19-negative plasma, reaching final concentrations ranging from 2.500 
down to 5 geq/ml. Twenty-four aliquots (140µl) of each virus dilution were prepared in 3 
independent sets of 8 and stored at –80°C until used. DNA-isolation was performed by 3 
operators, each one extracting viral DNA from 8 aliquots of the 10 dilutions-points. 
Extraction and amplification were shared out over a couple of days, using different lot-
numbers of the Viral RNA Mini Kit and PlatinumTaq-DNA Polymerase ®. Up to a 
concentration of 156 geq/ml a positive B19-TaqMan-PCR result was obtained in 100% 
(24/24) of the reactions (figure 1). The 95% cut-off value was calculated by Probit 
analysis and was determined to be 104 geq/ml, showing a 95% confidence interval of 70 
to 195 geq/ml. 
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Figure 1. Percent of positive results (Hit rate) found in dependence of the initial concentration of B19-
DNA. Dotted line: Interpolation for the calculation of the 95% cut-off value as determined by probit 
regression analysis.
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Precision of the assay 
For the determination of the intra- and inter-assay precision of the method, data sets 
from the utilised dilution series for determining the sensitivity limit were used. Eight 
replicates of each dilution were performed by one operator in one experiment under the 
same conditions. The remaining aliquots were processed by 2 operators over a period of 
4 days. The results for the mean threshold cycle and coefficient of variation of the 
highest and lowest concentration, found positive in 24 of 24 replicates, are given in 
Table 1. 
 
 
Table 1: Intra- and inter-assay precision of the assay 
 
Initial B19-DNA mean threshold % coefficient of  
 [geq/ml]  cycle   variation 
 
Intra-assay        2500   31.72   1.53     
precision (n=8)a    156   36.21   1.31     
 
Inter-assay  2500   31.60   1.24     
precision (n=16)b 156   35.97   2.80     
 
a Samples were processed under same operating conditions in one single experiment or 
b within different experiments carried out on different days by different operators using 
  different lot-numbers of used extraction kit and Taq DNA polymerase.  
  
 
Performance of the standard curve 
B19-DNA extracted from standard plasma containing 107 geq/ml was 10-fold diluted with 
water and used for generation of a standard curve. In figure 2 the obtained mean 
threshold cycles of each dilution from 8 different experiments are plotted against the 
initial template concentration corresponding to the B19-DNA level in the plasma sample. 
The shown standard deviations display the high coefficient of regression (> 0,99) found 
in all single experiments.  
 
Testing of B19 positive plasma samples 
To evaluate the installed assay regarding different isolates of Parvovirus B19-DNA, 
twelve B19 positive samples were tested. A positive result was obtained in each case.   
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Figure 2. Mean threshold cycles of each concentration of the standard curve calculated from 8 
independent experiments. Observed standard deviations from the highest to the lowest input-
concentration were as follows: 0.12, 0.22, 0.23, 0.35, and 0,37.  
 
DISCUSSION 
We developed and evaluated a B19 NAT assay based on the TaqMan-PCR technology. 
The advantages of the newly developed assay are its sensitivity and the possibility of 
distinguishing high from low virus titers of B19 in plasma samples by reliable 
quantification of B19-DNA. As the TaqMan-PCR works in a closed tube format, jointly 
with the use of an uracil-N-glycosylase system the chances of false-positive results 
caused by carry-over contamination are strongly decreased. 
A key issue, which defines the validity of a NAT procedure, is the use of an 
internal control. This is especially important in a blood bank setting. This issue was 
addressed by the design of a 180 base pair spanning B19-variant DNA fragment that 
was cloned into a pGEM-T-plasmid. The PCR product, which is generated from the B19-
variant DNA is identical to the wild-type fragment with the exception that the area where 
the hybridisation probe anneals is inverted. This variant DNA fragment assures that the 
characteristics of wild type DNA and internal control are as homologous as possible. 
Constructing the described sequence of the internal control as an oligonucleotide is an 
easy to handle alternative to the construction of an internal control DNA fragment by 
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PCR-based site-directed mutagenesis as previously described in several publications 
[16,21,22] 
Sequence diversities of the B19-parvovirus have been recently described. The 
majority of these variabilties are characterised by polymorphism’s in the VP regions and 
in the C-terminal region of NS1 [23,24,25]. Primers and wildtype-probe were chosen 
according to sequence alignments using the NCBI WebPage. The NS1-region amplified 
is highly conserved ensuring detection of various isolates of B19. This was confirmed by 
testing twelve B19 positive plasma samples, all giving a positive result. However, future 
isolates of B19-DNA could demonstrate base mismatches located in the amplified region 
of NS1, reducing the amplification efficiency of the described assay, especially in case of 
base substitutions located in the annealing sequence of the used wildtyp-probe [26]. 
Thus, even with regard to correct quantification, it would be useful to keep at least one 
additional PCR-assay, targeting an alternative region of the B19 genome. For example 
Aberham et al. described a quantitative, internally controlled real-time TaqMan-PCR 
assay for the detection of Parvovirus B19 DNA, targeting a conserved area in the VP1 
region of B19 [16].  
The data presented, demonstrates that the established B19-TaqMan-PCR assay 
is a sensitive and well standardised method that can be applied for large scale screening 
of single blood donations as well as plasma pools used for further manufacture into 
components. Since a quantitative assay is a prerequisite for the screening of plasma for 
production pools an absolute standard curve ranging from 102 to 106 geq/ml was 
constructed. The risk of false negative results due to inhibition or another failure of the 
amplification reaction is minimised by the use of an internal control. It was also shown, 
that purification of Parvovirus B19 DNA is possible using a silica membrane based 
extraction method for viral RNA. This circumstance allows the use of only one extraction 
step for screening blood donations for HCV-RNA, HIV-RNA and Parvovirus B19-DNA. 
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Up-regulation of tissue factor (TF) expression in circulating blood cells, especially 
monocytes, plays a key role in the pathogenesis of various thromboembolic diseases [1-
4]. Measurement of TF expression in monocytes therefore might be helpful in the 
diagnosis of a hypercoagulable state [5-7]. Monocytic TF expression can be measured 
on both the protein and RNA levels. Testing on the RNA level seems to be more 
appropriate than antigen testing to detect a procoagulant state because monocytes that 
already express functionally active TF on their membrane surfaces are rapidly cleared 
from the circulation [8]. 
The aim of the present study was to develop a protocol for quantitative determination of 
TF mRNA transcripts in monocytes and other circulating blood cells. The method should 
be rapid, robust, and applicable in whole blood without the need for cell isolation. We 
developed a one-step quantitative reverse transcription (qRT)-PCR assay based on the 
real-time TaqMan® technology and evaluated the preanalytical conditions required for 
the use of TF mRNA measurements on a routine clinical basis as well as several 
normalization strategies, including normalization based on CD14 and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) reference gene expression. Finally, we measured 
baseline TF expression in healthy individuals and in thrombophilic patients. 
RNA calibrators for quantification were prepared by in vitro transcription of DNA hybrids 
that combined the T7 promoter sequence with the following sequences of TF, CD14, or 
GAPDH cDNA: for TF, bp 265–848 (GenBank accession no. M16553); for CD14, bp 18–
564 (GenBank accession no. M86511); and for GAPDH, bp 8–525 (GenBank accession 
no. M33197). Generated RNAs were treated with DNase I (Roche) to remove the added 
DNA templates and purified by use of the RNeasy Mini Kit (Qiagen). RNA was quantified 
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by photometric measurement (A260 reading of 1 = 44 mg/L). Oligonucleotide primers and 
probes for TF and CD14 qRT-PCR were designed by use of Primer Express software, 
Ver. 1.5 (Perkin-Elmer), and were purchased from Eurogentec. All sequences shown in 
Table 1 were chosen to prevent amplification of genomic DNA. Primer and probe 
sequences for amplification of GAPDH mRNA were taken from the "TaqMan Gold RT-
PCR Kit" protocol (Perkin-Elmer). 
 
Table 1. List of primers and probes used for TF- and CD14-amplification  
 
qPCR Oligonucleotide Sequencea Positionb
 forward primer 5’-AATGTGGAGAGCACCGGTTC-3’ 415 – 434 
TF reverse primer 5’-CGTTCATCTTCTACGGTCACATTC-3’ 563 – 540 
 probe 5’-CACCTTACCTGGAGACAAACCTCGGA-3’ 473 – 498 
    
 forward primer 5’-AGAGCCTGTCCGGAGCTCA-3’    34 – 52 
CD14 reverse primer 5’-TCACAAGGTTCTGGCGTGG-3’ 152 – 134 
 probe 5’-ACGCGCGCTCCATGGTCGATA-3’    88 – 68 
 
a  TF- and CD14-probes were labeled with the fluorescent reporter dye FAM (6-carboxy- fluorescein) at 
the 5’ end and the quencher TAMRA (6-carboxytetramethyl-rhodamine) at the 3’ end. To enable multiplex 
reaction, a different reporter dye (JOE) was labeled at the 5’ end of the GAPDH-probe, while also TAMRA 
was used as a quencher at the 3’ end 
 
b  Positions according to GenBank accession numbers M16553 (TF) and M86511 (CD14) 
 
PCRs were performed in a final volume of 20 µL using the QuantiTect Probe RT-PCR-
Mix (Qiagen). Optimum reaction conditions were as follows: 1x Mastermix (including 
PCR buffer, deoxynucleotide triphosphates, 4 mM MgCl2, and Rox reference dye); TF or 
CD14 forward and reverse primers (200 and 150 nM, respectively); GAPDH forward and 
reverse primers (100 nM); TF or CD14 probe (200 nM); GAPDH probe (100 nM); 1 U of 
QT Probe RT Mix; and 5 µL (TF/GAPDH PCR) or 1 µL (CD14/GAPDH PCR) of calibrator 
or sample preparation. Calibrators and samples were run in duplicate. 
Thermal cycling was performed in a 96-well spectrofluorometric thermal cycler (Prism 
SDS 7700; Applied Biosystems) with the following profile: 50 °C for 20 min for the 
reverse transcription reaction; 95 °C for 15 min; and 40 cycles of denaturation for 20 s at 
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95 °C and annealing/extension for 60 s at 60 °C. The TF qRT-PCR performed in this 
way exhibited a linear range extending from 102 to 107 copies/reaction. The amplification 
efficacy (E) of 0.99 as determined from the slope (s) of the calibration curve according to 
the equation E = 10-1/s - 1 was not influenced by coamplification of GAPDH or CD14 
mRNA, making multiplex approaches possible. CV were calculated based on 
concentrations as determined by additional processed calibration curves. Intraassay CVs 
were <19%. Including the RNA isolation process, interassay CVs ranged between 3.1% 
and 21%. Variations of this magnitude are regular for quantitative PCR, and our results 
were well within accepted values for such assays. 
Accurate analysis of in vivo gene expression might be complicated by unintended ex 
vivo gene expression or degradation of gene transcripts. This is especially a problem 
when working with monocytes because monocytes are highly reactive and TF 
expression can be induced by contact with foreign surfaces and extended blood storage 
[9]. To minimize these ex vivo changes, we 
tested a blood sampling system (PAXgeneTM 
Blood RNA tubes; PreAnalytiX) that includes 
a stabilizing additive in the blood collection 
tube [10]. Whole blood from one healthy 
donor was drawn in parallel into PAXgene 
and EDTA tubes. Tubes were stored at room 
temperature or 4 °C, and total RNA was 
isolated after 0, 1, 3, 5, and 7 days of 
storage. TF, CD14, and GAPDH RNA 
concentrations remained stable up to 5 days 
of storage in PAXgene tubes at 4°C. 
Figure 1. Influence of sample handling on RNA 
stability. Whole blood was collected into PAXgene 
blood sampling tubes (closed symbols) or EDTA 
tubes (open symbols) and stored at 4°C (A) or at 
room temperature (B) over a total of 7 days. At the 
indicated time points the yield of RNA transcripts was 
measured by quantitative RT-PCR. TF (S); CD 14 
(), GAPDH (¡). 
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Storage at room temperature reduced this time span to 24 h. In EDTA-anticoagulated 
blood, the RNA expression profile dramatically changed within the first hours 
independent of the storage temperature (for details see Fig. 1). On the basis of these 
findings, we conclude that quantification of TF mRNA is reliable and reproducible only if 
the cellular RNA profile undergoes immediate stabilization after blood sampling. Methods 
that require isolation of peripheral blood mononuclear cells before RNA determination do 
not necessarily reflect the in vivo situation.  
Induction of monocytic TF expression by lipopolysaccharide (LPS) plays an important 
role in the pathogenesis of sepsis-associated thrombotic complications and has been 
investigated extensively in several in vitro studies [8, 11-13]. We therefore used the LPS 
model to evaluate the newly established PCR methods. As shown in Fig. 2A, increasing 
amounts of TF mRNA were quickly generated, and peak concentrations were reached 
between 1 and 2 h after exposure to LPS, followed by a progressive decrease thereafter. 
This pattern of TF mRNA expression agrees well with previously published data [11-13]. 
The LPS receptor CD14 has been proposed to be a suitable marker for the number of 
monocytic cells in blood [14]. This requires that CD14 mRNA expression is relatively 
constant and not regulated by different triggers. Studying CD14 expression patterns in 
the LPS model, we found LPS-independent but time-dependent changes in CD14 mRNA 
concentrations (Fig. 2B). Moreover, our data obtained on blood samples from healthy 
individuals demonstrate high interindividual variability of CD14 mRNA concentrations 
when normalized to the number of monocytes (range, 215–684 copies/monocyte), 
indicating that CD14 cannot be used as a marker for the number of monocytes. 
The use of monocytic TF mRNA as a diagnostic marker requires the definition of a 
reference interval. We established a reference interval from TF mRNA and monocyte 
measurements of 50 healthy blood volunteers (mean age, 33.0 years; range, 19–65 
years). The percentage of monocytes in whole-blood samples was determined by flow 
cytometry using a FACScan and CellQuest software, Ver. 3.3 (Becton Dickinson). 
Monocytes were identified by their specific forward and side scatter patterns and CD14 
expression. The mean (SD) transcription rate of 0.0041 (0.0021) TF mRNA 
copies/monocyte indicates very low basal TF expression that is 5 orders of magnitude 
lower than CD14 expression. The data showed a log-normal distribution, and a 95% 
reference interval of 0.0018–0.0095 TF transcripts/monocyte was calculated according 
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to IFCC guidelines [15]. As a consequence, a patient will be scored positive if monocytic 
TF expression exceeds 0.0115 transcripts/monocyte (upper limit of the reference interval 
+ 2 SD). 
Monocytes are the major, but may not be the only source of TF mRNA in whole blood 
[1,4]. At present it is a matter of discussion whether platelets contain TF mRNA and 
whether granulocytes can be induced to express TF mRNA [16,17]. To consider these 
potential TF mRNA sources, we also normalized TF mRNA results to the volume of 
whole blood. Using this mode of normalization, we calculated a 95% reference interval of 
685-3155 TF transcripts/mL. On the basis of these data, a patient will be scored positive 
if TF expression exceeds 4745 TF transcripts/mL. 
 
Figure 2. In-
vitro and in-
vivo studies of 
TF expression 
in blood cells. 
(A), EDTA-
anticoagulated 
whole blood 
(n=10) was 
stimulated with 
LPS (100 µg/L) 
at 37°C. 
Aliquots of 2.5 
mL were drawn 
from the whole 
blood samples 
at the indicated 
time points after 
addition of LPS 
and transferred to PAXgene Blood RNA tubes . The expression of TF mRNA (A) and CD14 mRNA (B) 
was then measured. O, results obtained with unstimulated samples (n=3). Results are expressed as mean 
values + s (error bars). TF mRNA was measured in blood samples obtained from 50 healthy blood donors 
and 27 thrombophilic patients. Results were normalized to the number of monocytes (C) or to the volume 
of whole blood (D). Boxes represent the interquartile range, with the median represented by the line inside 
the box. Whiskers indicate the highest and lowest values, excluding outliers (O) and extreme outliers (*). 
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The TF transcription profile was also analyzed in blood samples taken from 27 
thrombophilic patients (16 females and 11 males; mean age, 49.5 years; range, 18–83 
years). All patients had a positive history of at least one idiopathic deep venous 
thrombosis but showed no acute event in the last 3 months. The results shown in panels 
C and D of Fig. 2 show that these patients had statistically significant higher TF 
expression rates than the reference group. These findings suggest that increased TF 
expression in whole blood contributes to the procoagulant state in thrombophilic patients 
and support the findings of other groups [6,18]. Further studies on larger series of 
patients, however, are required to clarify whether increased TF mRNA concentrations in 
circulating blood cells are a thrombophilic risk factor. 
In summary, the TF multiplex approach described here allows rapid and quantitative 
determination of TF mRNA concentrations in whole blood without the need for cell 
isolation. Ex vivo changes in the expression pattern of blood cells were avoided by the 
use of blood-sampling tubes that contain RNA preservation and cell-fixing additives. 
Together with the established reference interval, this easy-to-perform method could 
provide a useful basis for further studies in clinical settings in which TF expression plays 
an essential role. 
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ABSTRACT 
Monocytes are a potential cellular target for the hemostatic agent desmopressin 
(DDAVP). Since activated monocytes typically express tissue factor (TF), we examined 
the effect of DDAVP on the expression of TF in monocytes. Ten healthy volunteers were 
injected with 0.3 µg/kg body weight DDAVP and blood was collected before and up to 6 
hours after DDAVP. A significant decrease (p<0.027) in monocyte counts was observed 
after DDAVP reaching a nadir at 1 hour. TF mRNA levels measured by quantitative real-
time RT-PCR showed a progressive and significant increase (p<0.001), peaking at 1 
hour after DDAVP. Increased TF gene activities were associated with increased TF 
activities as measured through the rate of factor Xa formation. Comparing the in vivo 
response to DDAVP with the in vitro response to LPS similar patterns of response were 
observed, but on a 100-fold lower level. In vitro exposure of monocytes with DDAVP 
failed to induce TF expression making a direct activating mechanism unlikely. We 
suggest an indirect mechanism that involves activation of monocytes through DDAVP 
stimulated endothelial cells in a P-selectin/PSGL-1-dependent manner. In conclusion, 
our data demonstrate induction of TF-dependent procoagulant activity on monocytes as 
an additional hemostatic mechanism of DDAVP. 
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INTRODUCTION 
Administration of desmopressin acetate (1-desamino-8-D-arginine vasopressin, 
DDAVP), a synthetic analogue of vasopressin, induces a rapid rise in plasma levels of 
factor VIII (FVIII) and von Willebrand factor (vWF) through activation of endothelial cells 
[1-3]. DDAVP was therefore introduced by Mannucci and coworkers as a 
pharmacological alternative to plasma-derived factor VIII preparations  in the treatment 
of patients with mild hemophilia A and von Willebrand´s disease [4]. In addition to these 
established indications DDAVP is now successfully used in the treatment of various 
acquired and inherited bleeding disorders including those where vWF and FVIII levels 
are within the normal range or even increased such as several platelet disorders [5-7]. 
Interestingly, DDAVP shortens the bleeding time in Bernard-Soulier patients [8-11], and 
in patients with severe von Willebrand´s disease treated with cryoprecipitate [12]. As 
Bernard-Soulier patients are characterized by a defect in the glycoprotein-Ib-IX-complex, 
the primary vWF receptor on the platelet surface, and patients with severe von 
Willebrand´s disease do not have vWF stores that could be mobilized by DDAVP, 
concerns were raised whether the hemostatic effect of DDAVP is sufficiently explained 
by its effect on the FVIII-vWF-axis [13]. 
 Monocytes, a blood cell type showing a wide phenotypic overlap with endothelial 
cells and in particular endothelial cells of microvascular origin [14] have been discussed 
to be an additional cellular target of DDAVP. Hashemi et al. have shown that DDAVP 
stimulates monocytes to release platelet-activating factor (PAF) that triggers the release 
of vWF from endothelial cells and activates platelets [15,16]. Consistent with these 
findings increased levels of PAF have been found within leukocytes after administration 
of DDAVP to patients with hemophilia A or vWD [17]. Additional evidence that DDAVP 
activates monocytes is given by monocyte-platelet interaction studies [18]. Using an in 
vitro model, Pereira et al. demonstrated enhanced binding of formaldehyde fixed 
platelets to DDAVP stimulated monocytes when compared with non-stimulated cells. 
The increase in platelet binding correlated with increased expression rates of the P-
selectin ligand (PSGL-1) that acts as a P-selectin counter receptor and is expressed by 
activated monocytes [19]. 
Typically, activated monocytes express functional active tissue factor on their 
plasma membrane. This has been shown for various activators such as endotoxin, 
60 
immune complexes, proinflammatory cytokines, and platelets [19-22]. Tissue factor (TF) 
binds factor VII (FVII) and activated FVII (FVIIa) to form the TF/FVIIa complex that 
activates the coagulation cascade by conversion of factors IX and X into the active 
enzymes [23]. If DDAVP activates monocytes, a procoagulant shift should be induced 
through induction of TF expression. To test this hypothesis, ten healthy volunteers were 
treated with DDAVP and time-dependent changes in monocytic TF expression levels 
were recorded on the transcriptional and translational level.   
DDAVP action is mediated through the type 2 vasopressin receptor (V2R) [24]. 
This receptor subtype is expressed in the kidney collecting duct where it mediates the 
antidiuretic effect of DDAVP and on microvascular endothelial cells where it mediates 
the release of vWF and t-PA [13]. Although vasopressin receptors have been identified 
on human peripheral blood mononuclear cells [25], expression of the type 2 variant has 
not been conclusively demonstrated [13]. To determine whether the DDAVP action on 
monocytes occurs through a direct, possibly V2R-dependent mechanism, or by an 
indirect mechanism we performed in vitro incubations of whole blood and isolated 
monocytes with DDAVP.  
 
PATIENTS AND METHODS 
Study population and administration of DDAVP 
Ten healthy volunteers (mean age, 27.2 years, range 20 - 41 years) received an 
intravenous infusion of DDAVP (Minirin®, Ferring Arzneimittel, Kiel, Germany) in a dose 
of 0.3 µg/kg b.w. diluted in 50 ml 0.9 % NaCl over 15 minutes. All subjects were in good 
health, as documented by history, physical examination, and hematologic and 
biochemical screening. Blood samples for hematologic and coagulation parameters, 
mRNA isolation, and monocyte isolation were taken from the antecubital vein some 
minutes before DDAVP-administration, immediately after end of DDAVP infusion and 
every 1 hour after initiation of DDAVP-treatment over a time-period of 6 hours. The study 
was approved by the institutional ethics committee for human subjects. Informed 
consent was obtained from all volunteers.  
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Hematologic parameters and monocyte isolation 
Global white cell counts were measured in blood samples collected in tubes containing 
EDTA using a Sysmex K-4500 (Sysmex, Norderstedt, Germany). The percentage of 
monocytes was determined by flow cytometry using a FACScan and CellQuest software 
version 3.3 (Becton Dickinson (BD), Basel, Switzerland). Fifty microliters of EDTA-
anticoagulated whole blood was labeled with fluorescent dye conjugated mouse 
monoclonal antibodies (10 µl each, BD) against human CD45 (phycoerythrin-(PE)-
conjugated) and human CD14 (fluorescein-(FITC)-conjugated). As negative control, 10 
µl each mouse IgG1 (PE) and IgG2a (FITC) antibodies (BD) were added to 50 µl whole 
blood. All samples were incubated for 20 min at room temperature in the dark. 
Afterwards, 500 µl FACS lysis solution (BD) were added and samples measured directly 
after complete lysis of red cells. At least 20,000 CD45 positive events were recorded 
and monocytes were gated by their specific forward and side-scatter pattern. 
Furthermore, the monocyte population was identified by high CD14 expression.  
Peripheral blood mononuclear cells (PBMCs) were isolated from 8 ml of whole 
blood using cell preparation tubes (CPT, BD).  
 
Determination of FVIII-activity and vWF antigen 
All measurements of coagulation parameters were performed in citrated platelet-poor 
plasma. FVIII activity was determined by an one-stage clotting assay using FVIII-
deficient plasma (Dade-Behring, Marburg, Germany) prepared by immunoadsorption. 
The assay was performed on an automated clotting analyzer (Amax, Pharmacia, 
Germany). Plasma levels of vWF-antigen were determined using a sandwich ELISA 
(Vidas vWF, bioMérieux, Marcy-l´Etoile, France).  
 
TF mRNA analysis 
To minimize modulation of the mRNA profile ex vivo, isolated PBMCs (adjusted to 
aliquots of 2 x 106 cells) were lysed using 600 µl cell lysis buffer (buffer RLT, RNeasy 
Mini Kit, Qiagen) containing 1% (v/v) ß-mercaptoethanol. The cell lysates were stored at 
-80°C until isolation of RNA. Total RNA was isolated using the RNeasy Mini Kit (Qiagen, 
Hilden, Germany) according to the manufacturer´s instructions. Isolated RNA was eluted 
in 50 µl of RNase free water.  
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 TF- and GAPDH-mRNA were quantified using a multiplex real-time reverse 
transcription (RT) PCR protocol as previously described [26]. The quantitative TF-RT-
PCR performed in this way exhibited a linear range extending from 102 - 107 TF mRNA 
copies/reaction and reproducibility with coefficients of variation < 20%. In vitro 
transcripted TF RNA and GAPDH RNA were used as standard material. Results were 
normalized to the number of monocytes. 
 
Factor Xa generation assay 
The TF-dependent procoagulant activity of monocytes was measured using a factor Xa 
generation assay. Isolated PBMCs were resuspended in cell buffer (21 nM HEPES, 137 
mM NaCl, 5 mM KCl, 0.75 mM Na2HPO4, 5.5 mM glucose, 2 mM CaCl2, pH 7.4) to 
reach a final concentration of 2.5 x 106 monocytes/ml and 200 µl of this cell solution 
were added to a 96-well microtiter plate (Polysorb, Nunc, Roskilde, Denmark). Cells 
were overlaid with 100 µl CaCl2 (25 mM), and 100 µl of defibrinated normal human 
plasma. Defibrinated plasma was used as a source for FVII/FVIIa and factor X and was 
prepared by addition of 1 ml reptilase (0.7 U; Pentapharm, Switzerland) to 5 ml of 
plasma. After incubation for 5 min fibrin was removed by centrifugation for 5 min at 
10,000 x g. The fibrinogen free supernatant was aliquoted at 500 µl and stored at -80 °C 
until used. After incubation of the reaction mixture for 10 minutes at 37°C, cells were 
depleted by centrifugation (5 min, 150 x g) and 80 µl of cell free supernatant were added 
to a well of a 96-well microtiter plate containing 80 µl Tris/EDTA (20 mM/4 mM) and 40 
µl of the chromogenic substrate S2765 (2 mM; Chromogenix, Mölndal, Sweden). FXa 
generation was monitored by measuring the change of absorbance at 405 nm. A 
calibration curve was constructed using recombinant TF (Innovin, Dade-Behring, 
Marburg, Germany). This TF reagent was assigned a value of 1,000 arbitrary units (U) of 
TF-dependent procoagulant activity. The assay performed in this way was sensitive up 
to 0.005 U/106 cells. The interassay variability ranged from 6.9 % to 11.3 % for TF 
activities between 1 and 0.005 U/106 cells, respectively. 
 
FACScan analysis of monocytic TF antigen expression 
Either 50 µl of whole blood or a cell suspension at a concentration of 107 cells/ml 
(PBMCs) were incubated with 10 µl FITC-labelled mouse monoclonal anti human TF 
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antibody (American Diagnostica Inc, Greenwich, CT) and 10 µl PE labelled anti-CD14 
antibody for 60 minutes at 4°C. As negative control, 10 µl each mouse IgG1 (FITC) and 
IgG2a (PE) antibodies (BD) were used. After incubation, cells were washed with ice-cold 
PBS containing 0.1 % BSA (wt/vol). After washing, cells were resuspended in PBS 
containing 1 % BSA and analyzed. Monocytes were gated by their specific forward and 
side-scatter pattern. Furthermore, the monocyte population was identified by high CD14 
expression. A total of 20,000 events was recorded for each file. Specific TF antibody 
binding was expressed as mean fluorescence intensity (MFI) of the monocyte 
population.  
 
In vitro stimulation experiments 
Anti-coagulated whole blood from 5 healthy volunteers was used to perform DDAVP 
stimulation experiments with monocytes. Individual blood samples were sub sampled 
into 1 ml aliquots and DDAVP was added to achieve final concentrations from 10 to 100 
ng/ml. A non-stimulated sample series was processed in parallel as a negative control. 
After the incubation levels of TF-mRNA and cell surface expressed TF antigen were 
measured as outlined before.   
 To determine the stimulation potential of monocytes, whole blood was drawn from 
study participants at least 24 hours before administration of DDAVP. PBMCs were 
isolated, adjusted to 2 x 106 cells in 1 ml RPMI and incubated for 3 h in the absence or 
presence of 1 µg/ml LPS. All incubation steps were performed at 37°C in 15 ml 
polypropylen tubes. After the incubation expression levels of TF-mRNA were measured 
by quantitative TaqMan-PCR. Results were normalized to the number of monocytes 
present in the sample preparation.  
 
Statistical analysis 
Data were analyzed using SPSS 9.1 for Windows software. The student’s t-test was 
used to determine statistical significance between various data sets. Statistical 
significance was judged at confidence levels greater than 95% (p<0.05). All results were 
expressed as mean ± standard deviation. 
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RESULTS 
Hematologic and coagulation parameters in DDAVP-treated subjects 
Administration of DDAVP was associated with a rise in FVIII activity and vWF plasma 
levels. It also induced a change in leukocyte counts, involving monocytopenia and 
neutrophilia (Fig. 1). Mean values of leukocyte counts increased from 6.75 x 103/µl 
before DDAVP to a maximum of 9.2 x 103/µl reached at 3 h after DDAVP (p < 0.001). 
Monocyte counts (mean value before DDAVP: 0.6 x 103/µl) decreased immediately after 
DDAVP administration reaching a nadir (mean value: 0.2 x 103/µl) at 1 h after DDAVP (p 
= 0.027). Two to 3 hours after DDAVP administration monocyte counts returned to 
baseline levels. Platelet counts were not influenced by DDAVP administration. 
A            B 
 
 
Figure 1. Time course of leukocyte and monocyte counts after DDAVP administration. (A) 
DDAVP administration induced a significant increase (p < 0.001) in leukocyte counts starting 2 hours 
after DDAVP and reaching a maximum 3 h after DDAVP. (B) Immediately after DDAVP infusion the 
number of monocytes decreased reaching a minimum 1 h after DDAVP (p = 0.027). Boxes represent 
the quartile range, with the median represented by the line. Whiskers at the top and the bottom of the 
box show the highest and lowest values, excluding outliers (o) and extreme outliers (*). 
 
In vivo kinetics of tissue factor expression after DDAVP administration 
Starting from a baseline value of 0.0071 + 0.00354 (mean + SD) TF copies/monocyte TF 
mRNA levels rapidly increased reaching a peak of 0.0366 + 0.00363 (mean + SD) TF 
copies/monocyte at 1 h after DDAVP administration. The results shown in figure 2A 
represent the increase over time after DDAVP administration relative to baseline levels. 
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With a p-value of 0.001 the increase to 377 % was statistically significant. At three hours 
after DDAVP administration TF mRNA levels were returned to baseline values. Among 
the study population, only 1 volunteer showed no detectable increase in TF mRNA 
levels.  
Basal levels of monocytic TF activity measured through the rate of FXa-formation 
were below the detection limit of the assay of 5 mU/106 cells. DDAVP administration 
induced a biphasic but statistically not significant response with a moderate increase to 
8.9 + 1.3 (mean + SD) mU/106 cells at 2 hours after DDAVP and a second increase 
between 4 and 5 hours after DDAVP (16.4 + 0.4 mU/106 cells, p = 0.08) (Fig. 2B). 
Statistical significance was not reached, because of the high interindividual variability in 
TF activity levels.  
However, TF-antigen levels on monocytes measured by FACS analysis showed 
no significant increase after administration of DDAVP. Binding patterns of the 
corresponding control antibody were similar to that of the TF-specific antibody excluding 
any changes of MFI (FITC) caused by changes of TF antigen expression on the 
monocytic surface. 
A            B 
 
 
Figure 2. Changes in TF expression levels over time after DDAVP administration. (A) Blood 
samples were taken at the indicated time points and TF mRNA levels were quantified using the real 
time TaqMan PCR approach. Results were normalized to the number of monocytes. (B) Surface 
expressed TF activity was analyzed by a FXa-generation assay. For details of box plots see figure 1.  
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In-vivo DDAVP-induced TF expression versus ex-vivo LPS-induced TF expression 
The effect of LPS (1 µg/ml) upon the rate of TF transcription was examined in PMBCs 
obtained before administration of DDAVP. LPS treatment induced an increase that 
ranged from 178-fold to 410-fold (mean: 311-fold) after 3h of incubation. Figure 3 shows 
a linear plot of TF mRNA levels of in vitro stimulated monocytes against the maximal 
rate of TF mRNA stimulation measured after in vivo DDAVP stimulation. Although LPS-
stimulation induced a 50 to 150 fold higher increase in TF expression levels than the 
DDAVP stimulated response, the relative increase was identical. Low responders to LPS 
reacted also mild to DDAVP and vice versa in high responders. 
 
Figure 3. Monocytic TF expression 
induced by in-vitro lipopolysaccharide 
stimulation compared with ex-vivo results 
after DDAVP administration. PBMCs were 
isolated from study patients 2 - 3 days before 
DDAVP administration and incubated with 1 
µg/ml lipopolysaccharide for 3 hours at 37°C. 
Following incubation TF mRNA levels were 
quantified (X-axis) and compared with the TF 
stimulation rate at 1 hour after DDAVP 
administration (Y-axis) from the same study 
patient. 
 
TF mRNA and TF antigen analysis in whole blood cells and monocytes after in 
vitro DDAVP stimulation 
To assess direct effects of DDAVP on monocytes, whole blood or isolated PBMCs 
obtained from 5 volunteers were incubated with DDAVP (10 - 100 ng/ml, 8.45 - 84.5 nM) 
at 37°C and the time-dependent expression of monocytic TF measured. There was no 
time- or concentration-dependent increase in TF mRNA levels whereas the response to 
LPS was regular. In addition, TF antigen was not modulated independent of the 
presence or absence of DDAVP (data not shown).  
To study whether monocytes are activated by an activator that is released into plasma in 
response to DDAVP, we incubated purified PBMCs with plasma that was obtained from 
individuals immediately and at 1 hour after DDAVP administration (DDAVP conditioned 
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plasma). PBMCs were isolated from the same individuals after a washout period of 7 
days, mixed with DDAVP conditioned plasma to reach a final concentration of 2.5 x 106 
cells/ml, and incubated at 37°C. Normal human plasma was used as negative and LPS 
containing plasma (100 ng/ml) was used as positive control. There was no difference in 
TF gene activities (shown in figure 4), monocytic TF activity and TF-antigen levels 
between DDAVP conditioned plasma and normal control plasma.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. In vitro stimulation of isolated monocytes with plasma obtained after DDAVP 
administration. Plasma was collected 1 hours after DDAVP treatment and incubated with PBMCs at 
a final concentration of 2.5 x 106 cells. At the indicated time points TF mRNA levels were analyzed. 
Normal human plasma and plasma supplemented with LPS (100 ng/ml) were used as negative (▲) 
and positive (z) controls. Results are expressed as mean + SD.
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Discussion 
In the present study, we showed that administration of DDAVP induced a TF-dependent 
procoagulant activity on monocytes, the effect activates coagulation and involves the 
interaction between DDAVP-activated endothelial cells and monocytes. 
The effect of DDAVP on FVIII and vWF levels only partially explains the 
hemostatic action of the drug [13]. Searching for additional cellular effects of DDAVP we 
focussed our interest on monocytes. Activation of monocytes in response to DDAVP has 
been shown by in vitro studies. Incubation of whole blood or purified monocytes with 
DDAVP induced the release of platelet activating factor and enhanced the binding of 
activated platelets to monocytes in a P-selectin/PSGL-1-dependent manner [15,16,18]. 
At present, however, there is only one in vivo study available that reports enhanced 
levels of intracellular platelet activating factor within leukocytes after administration of 
DDAVP to patients with hemophilia A or von Willebrand disease [17]. Thus, the 
contribution of activated monocytes to the hemostatic action of DDAVP remains unclear. 
Typically, activation of monocytes induces TF expression. This is documented for 
a variety of activators such as endotoxin, immune complexes, certain cytokines, and 
activated platelets [23,27]. Monocytic TF belongs to the so called intravascular or blood-
borne TF moiety and is able to activate coagulation [28]. Assuming that monocytes are 
activated in response to DDAVP one should expect induction of TF expression. To test 
this hypothesis, healthy volunteers were treated with DDAVP and monocytic TF 
expression levels measured.  
All of the ten individuals responded regularly to DDAVP as indicated by a rapid 
rise in plasma levels of vWF and FVIII. Leukocyte counts showed a biphasic change 
involving monocytopenia followed by neutrophilia. This pattern is nearly identical to the 
changes in leukocyte counts observed in the human endotoxemia model where the 
decrease in monocytes was associated with a clear pattern of TF mRNA expression 
[21]. Identical results were obtained in our DDAVP treated study group. TF mRNA 
expression was induced after DDAVP, showed peak levels between 1 and 2 hours after 
DDAVP followed by a progressive decline and immediate normalization thereafter.  
Studying TF activity on monocytes through FXa formation and TF antigen 
expression by FACS analysis we found only a moderate and statistically not significant 
increase in TF. This again is in agreement with the findings in human endotoxemia and 
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is most likely caused by adhesion of activated monocytes to endothelium. It has been 
shown that expression of functional active TF promotes adhesion of monocytes to the 
endothelial surface [29]. In this case, preferentially, monocytes with poor TF antigen 
expression will remain in the blood circulation. Such an explanation would also imply 
that the induction of mRNA expression of TF in the retained monocytes might be even 
higher than shown in our data and that we are detecting monocytes with a relatively poor 
response to DDAVP.  
Our results indicate inter-individual differences in monocytic TF expression upon 
DDAVP stimulation. A high degree of inter-individual variation has also been reported for 
endotoxin stimulation [30]. To study whether both variations correlate we compared the 
in-vivo response to DDAVP with the ex-vivo response to LPS. There was a strong 
positive correlation between both agonists suggesting strongly related intracellular 
activation pathways.  
Activation of endothelial cells through DDAVP is mediated through interaction with 
the vasopressin receptor type 2. At present, however, there are conflicting data whether 
monocytes express functional active V2R. While Block et al. give indirect evidence for 
the presence of V2R through binding of labelled DDAVP to monocytes [31], others were 
not able to detect this receptor subtype in monocytes by RNA expression studies [25]. In 
our in vitro studies there was no TF expression detectable after stimulation of monocytes 
with DDAVP. In addition, plasma obtained from DDAVP-treated patients was not able to 
induce TF expression in monocytes. These data make it most likely, that monocyte 
activation occurs through a mechanism that requires interaction of monocytes with 
DDAVP-activated endothelial cells rather than through a direct V2R-dependent 
mechanism. We propose a cellular model that involves activation of monocytes on the 
surface of DDAVP-activated endothelial cells (Fig. 5). DDAVP induced exocytosis of 
Weibel-Palade-bodies translocates P-selectin in the endothelial cell plasma membrane. 
P-selectin mediates leukocyte rolling and upon interaction with its counter receptor 
PSGL-1 on monocytes upregulates the de novo synthesis of TF in monocytes as 
previously described by Celi and others [20]. Thus, DDAVP activated endothelial induce 
the TF pathway on the surface of monocytes as an additional hemostatic mechanism.   
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Figure 5. A proposed model of monocytic TF induction by DDAVP. Binding of DDAVP (1) to the 
vasopressin 2 receptor (V2R) activates endothelial cells in a cAMP-dependent manner (2) resulting in 
exocytosis of Weibel-Palade-bodies (WPB). Von Willebrand factor (vWF) and other components of 
WPBs such as IL-8 are secreted (3) while P-selectin, a membrane component of WPBs, is inserted in 
the plasma membrane (4) of the stimulated endothelial cell. Through P-selectin/P-selectin ligand 
(PSGL-1) interaction monocytes (M) adhere to the endothelial cell surface and become activated to 
express tissue factor (TF) (5). Tissue factor expression is further augmented by secreted IL-8 (3).  
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ABSTRACT 
BACKGROUND: Genetic analysis of platelet mRNA may facilitate the diagnosis of 
disorders affecting the megakaryocytic-platelet lineage. Its use, however, is limited by 
the exceptionally small yield of platelet mRNA and the risk of leukocyte contamination 
during platelet preparation. METHODS: We depleted platelet suspensions of leukocytes 
by filtration and used a PCR-based RNA amplification step [switching mechanism at the 
5' end of RNA templates (SMART)]. We tested the reliability and precision of the RNA 
amplification procedure by use of real-time PCR to measure quantities of specific 
transcripts: von Willebrand factor (vWF), A-subunit of coagulation factor XIII (F13A), and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Microarray analysis was 
performed on platelet RNA with and without amplification. RESULTS: Microgram 
quantities of platelet-specific cDNAs were produced from as little as 50 ng of total 
platelet RNA or 40 mL of whole blood. At cycle numbers <16, amplification of all 
transcripts tested was exponential with slightly more efficient amplification of low-
abundance transcripts. Expression profiling of 9850 genes gave identical results for 
9815 genes (1576 positive/8239 negative). Eight transcripts failed to be amplified by the 
SMART procedure. Expression of vWF, F13A, and GAPDH transcripts showed only 
minor day-to-day variations in three healthy individuals. CONCLUSION: The proposed 
protocol makes extremely small amounts of platelet RNA available for gene expression 
analysis in single patients. 
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INTRODUCTION 
Platelets are anucleated but contain small amounts of mRNA. This mRNA is of 
megakaryocytic origin and is translationally active [1]. Recently, the platelet 
transcriptome was profiled by microarray analysis [2,3]. At the same time, the platelet 
proteome was defined by highresolution 2-dimensional polyacrylamide gel 
electrophoresis [4]. Combining of these data has enabled the molecular anatomy of 
human platelets to be resolved as a tool for better understanding of normal and 
pathologic platelet function [5,6]. 
Analysis of the platelet transcriptome in patients, however, is limited by the 
exceptionally small yield of platelet mRNA. Thus, more than 1x1012 platelets, 
representing more than 5000 mL of whole blood, are usually required to obtain 1-4 µg of 
poly(A)+ RNA [7]. Platelet apheresis offers the only chance of obtaining such a high 
number of platelets from a single donor, but this approach cannot be performed in 
patients with platelet disorders [8].  
Techniques that amplify the starting mRNA may overcome these limitations [9-
11]. At present, two amplification strategies are typically used for RNA amplification; 
both include reverse transcription, which is followed either by exponential PCR 
amplification [12-15] or by T7-based linear in vitro transcription [16-19]. To minimize the 
amount of whole blood needed for platelet gene expression analysis in a single patient, 
we decided to use an exponential PCR amplification method, the switching mechanism 
at the 5’ end of RNA templates (SMART) technique [12]. The main concern about 
amplification procedures, especially with PCR-based methods, is that they provide 
genetic information with high yield but an altered gene expression profile [10,17,20,21].  
We carefully evaluated this aspect by comparative microarray analysis and by 
quantitative PCR. In the microarray experiments, original and amplified platelet RNA 
was profiled across 9850 genes. To determine the bias between transcript ratios, 
selected transcripts were quantified by real-time PCR during the amplification process. 
von Willebrand factor (vWF) was selected for two reasons: (a), with a length of 8.3 kb, 
vWF mRNA is one of the longest human messages; and (b), it is expressed exclusively 
in platelets and endothelial cells. We selected RNA coding for subunit A of coagulation 
factor XIII (F13A) as a second platelet typical RNA. This 3.8-kb spanning RNA 
represents the group of medium-sized RNAs and is highly expressed in platelets [2,3,5 
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6]. Recently, expression of fibrinogen α-chain (FGA; 2.2 kb) has been found in platelets 
by array analysis. It has been ranked in position 632 of the most abundant platelet 
messages, lying between F13A (rank 199) and vWF (rank 2465) [5]. On the basis of 
these data, we decided to use FGA as an additional candidate RNA representing 
platelet RNAs that are expressed in low to moderate concentrations. Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was chosen because this 1.3-kb gene is highly 
expressed in nearly all cells, including platelets.  
Because the concentration of mRNA in platelets is much lower than in leukocytes, 
a small number of leukocytes can distort platelet gene expression profiles [22]. To 
address this problem, we included a leukocyte depletion step in the platelet preparation 
protocol and monitored its efficiency by analyzing leukocyte-specific gene products. 
Finally, we tested the reproducibility and sensitivity of our approach and the day-to-day 
variations by measuring the amounts of vWF, F13A, and GAPDH RNA over time in three 
healthy individuals. 
 
MATERIALS AND METHODS 
Isolation and preparation of platelets  
For large-scale RNA preparation, platelets were collected from healthy blood donors by 
platelet apheresis on an Amicus Crescendo cell separator (Baxter). Each 
leukocytereduced apheresate contained >2x1011 platelets in 200–300 mL of autologous 
plasma. Contaminating leukocytes (>1x106 per unit of apheresate) were completely 
removed by filtration (PXL2; Pall Biomedizin) as judged by flow cytometric analysis 
(LeucoCountTM; Becton Dickinson). The platelets were washed with Tyrode’s buffer and 
collected by centrifugation at 1000g for 15 min, after which the platelet pellets were 
frozen in liquid nitrogen and stored at -80 °C. To obtain RNA from a single donor blood, 
we collected 20–80 mL of citrate-anticoagulated blood from healthy volunteers. Platelets 
were separated from erythrocytes by centrifugation at 150g for 20 min at room 
temperature. The upper two thirds of the plateletrich plasma (PRP) was resuspended in 
twice a volume of Tyrode’s buffer, filtered through a Purecell PL leukocyte removal filter 
(Pall Biomedizin), and processed as described above.  
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RNA extraction  
For microarray analysis, total RNA was isolated from six single donor platelet apheresis 
concentrates after leukocyte depletion with the use of TRIzol reagent (Invitrogen) as 
described previously [3]. From each platelet concentrate with total platelet numbers in 
the range of 2.4–2.8x1011 (mean, 2.7x1011) we could obtain 18.5–28.2 µg (mean, 22.5 
µg) of total RNA. When we worked with whole blood, we directly extracted mRNA from 
isolated platelets with oligo(dT)-coupled paramagnetic beads [Dynabeads Oligo(dT)25; 
Dynal] according to the procedure described by Jakobsen et al. [23]. Bead-coupled 
platelet mRNA was eluted in 10 µL of RNase-free water. 
 
cDNA generation and amplification 
Platelet RNA was transcribed to cDNA and subsequently amplified by SMART 
technology (BD Biosciences Clontech) according to the manufacturer’s instructions. 
Samples were amplified in a PTC-200 thermal cycler (MJ Research, Biozym 
Diagnostika, Hess) by use of the following program: 95 °C for 1 min, then 2–18 cycles at 
95 °C for 15 s, 58 °C for 30 s, and 68 °C for 6 min. After every two cycles, 5 µL of the 
reaction mixture was transferred to a fresh tube and kept at 4 °C; the remaining mixture 
was subjected to additional cycles.   
 
Quantitative real-time PCR  
One-step quantitative real-time reverse transcription-PCR (RT-PCR) was used for 
measuring the concentrations of RNA transcripts coding for vWF, FGA, F13A, and 
GAPDH. Oligonucleotide primers and probes for quantification of vWF and FGA 
transcripts were designed by use of Primer Express software, Ver. 1.5 (Perkin-Elmer). 
Primer and probe sequences for amplification of GAPDH mRNA were taken from the 
TaqMan Gold RT-PCR Kit protocol (Perkin-Elmer). Oligonucleotides for quantification of 
vWF, FGA, and GAPDH transcripts were purchased from Eurogentec. Detailed 
sequence information is provided in Table 1. For quantification of F13A transcripts, we 
used a predeveloped primer/probe set from Applied Biosystems (Assay-on-DemandTM 
product, containing a 5’-6-carboxyfluorescein-labeled MGB® probe with a black hole 
quencher at the 3’ end). Corresponding sequence information was not available. All 
77
78 
sequences were chosen to prevent amplification of genomic DNA by overlapping or 
spanning exon/intron boundaries.  
 
Table 1. Oligonucleotide primers and probes used for quantitative PCR. 
Target mRNA Oligonucleotide Sequencea Positionb
FGA Forward primer 5’-AAGTACAGCATATCCAGCTTCTGC-3’ 473 - 496 
 Reverse primer 5’-CCTCGACAAGATCGGATCTTAA-3’ 575 – 554 
 Probe 5’-TCAATGTCCACCTCCAGTCGTTTCA-3’ 551 - 527 
    
vWF Forward primer 5’-TCTGTGGATTCAGTGGATGCA-3’ 5720-5740 
 Reverse primer 5’-CGTAGCGATCTCCAATTCCAA-3’ 5804-5784 
 Probe 5’-CGCCAGGTCCAACAGAGTGACAGTGT-3’ 5752-5777 
    
GAPDH Forward primer 5’-GAAGGTGAAGGTCGGAGTC-3’ 81 – 99 
 Reverse primer 5’-GAAGATGGTGATGGGATTTC-3’ 306 – 287 
 Probe 5’-CAAGCTTCCCGTTCTCAGCC-3’ 277 - 258 
 
a FGA- and vWF-probes were labeled with the fluorescent reporter dye 6-carboxyfluorescein (FAM) at the 5’end and 
the quencher 6-carboxytetramethylrhodamine (TAMRA) at the 3’end. To enable multiplex reactions, a different 
reporter dye (JOE) was labelled at the 5’end of the GAPDH-probe, but TAMRA was still used as quencher at the 
3’end. 
b Nucleotide positions based on the GenBank accesssion numbers J00127 (FGA), NM_000552 (vWF), and 
NM_002046 (GAPDH). 
 
Quantitative RT-PCR reactions were performed with the QuantiTect Probe RT 
PCR Kit (Qiagen). Reactions were performed in a final volume of 20 µL containing 1x 
master mixture (including PCR buffer, deoxynucleotide triphosphates, 4 mM MgCl2, and 
ROX reference dye), FGA or vWF forward and reverse primers (150 nM each), GAPDH 
forward and reverse primers (100 nM each), FGA or vWF probe (200 nM), GAPDH 
probe (100 nM), 0.2 µL of QT Probe RT Mix, and 1 µL of each dilution of calibrators and 
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samples. For quantification of F13A transcripts, 1 µL of the primer/probe mixture was 
added to each reaction. Samples were amplified in a 96-well spectrofluorometric thermal 
cycler (ABI Prism SDS 7700; Applied Biosystems) using the following program: 50 °C for 
30 min, 95 °C for 15 min, 40 cycles at 94 °C for 15 s, and 60 °C for 1 min.  
To measure amplified cDNA, we performed real-time PCR using probes and 
primers identical to those used for the quantitative RT-PCR. Multiplex reactions were 
performed in a final volume of 25 µL containing 1x PCR buffer [20 mM Tris-HCl (pH 8.5), 
50 mM KCl], 4 mM MgCl2, 200 mM each deoxynucleotide triphosphate, 0.5 µL of ROX 
reference dye, 1.25 U of PlatinumTaq DNA polymerase, and 1 µL of each calibrator or 
sample preparation. Oligonucleotide concentrations were the same as those described 
for RT-PCR reactions. PlatinumTaq DNA polymerase and ROX reference dye were 
purchased from Invitrogen. Thermal cycling using the Prism SDS 7700 was performed 
with the following profile: 95 °C for 5 min followed by 40 cycles consisting of 20 s of 
denaturation at 95 °C and 60 s of annealing and extension at 60 °C.  
All calibrators and samples were run in duplicate. 
 
RNA synthesis and calibrator preparation  
RNA calibrator for absolute quantification of vWF and GAPDH transcripts were prepared 
by in vitro transcription. Starting points were PCR-amplified cDNAs coding for vWF and 
GAPDH that were cloned in the SrfI site of pPCR-Script Amp SK (+) (Stratagene). These 
constructs were used to generate DNA templates containing a T7 RNA polymerase 
promoter sequence at their 5’ end with the following sequences of vWF and GAPDH 
downstream: for vWF, bp 5633–5919 (GenBank accession no. NM_000552); and for 
GAPDH, bp 8–525 (GenBank accession no. M33197). In vitro transcription was 
performed with these modified DNA templates using T7 RNA polymerase (Invitrogen) 
according to the manufacturer’s instructions. After digestion of DNA templates with 
DNase I (Roche), RNAs were purified by use of the RNeasy Mini Kit (Qiagen). RNA was 
quantified by photometric measurement (A260 reading of 1 = 44 mg/L). All RNA stock 
solutions were stored at -70 °C. Total placental RNA (BD Biosciences Clontech) was 
used for relative quantification of F13A transcripts. One unit was defined as the number 
of F13A transcripts present in 10 pg of the placental RNA.  
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Calibrators for quantification of SMART-generated vWF and GAPDH cDNA 
products were prepared from cDNA plasmids containing the sequences described 
above. The plasmids were isolated from transformed XL10-Gold (Stratagene) cultures 
and quantified by photometric measurement (A260 reading of 1 = 50 mg/L). The DNA 
concentration is expressed in molecules/mL. All DNA stock solutions were stored at -70 
°C. For relative quantification of SMART-generated F13A sequences, total placental 
RNA was transcribed to cDNA by use of Super- Script RNase H- reverse transcriptase 
(Invitrogen). 
 
Comparative microarray analysis 
To compare gene expression profiles from platelet RNA with and without amplification, 
we used total RNA isolated from single donor platelet apheresis concentrates in six 
individual experiments. Unamplified samples were fluorescently labeled by use of 10 µg 
of platelet RNA, Cy3- or Cy5-dCTP (Amersham Biosciences), and the LabelStar 
reagents (Qiagen). Amplified samples were generated each from 0.5 µg of total platelet 
RNA by use of the SMART fluorescent probe amplification reagents (BD Biosciences 
Clontech) according to the manufacturer’s protocol. The SMART PCR products were 
further processed by random primed labeling with aminoallyl-dUTP. Aminoallyl-labeled 
DNA was then labeled with Cy3 or Cy5 by use of monoreactive dyes (Amersham 
Biosciences). The differential labeling of the six RNA samples was performed as follows: 
RNA samples 1, 2, and 3 were labeled with Cy3 without amplification and labeled with 
Cy5 after SMART amplification; RNA samples 4, 5, and 6 were labeled with Cy5 without 
amplification and with Cy3 after SMART amplification. 
Before the hybridization on microarray glass slides representing 9850 human 
genes (MWG-Biotech AG), the Cy3- and Cy5-labeled samples were combined as 
follows: slide 1, unamplified sample 1 (Cy3) + unamplified sample 4 (Cy5); slide 2, 
unamplified sample 2 (Cy3) + unamplified sample 5 (Cy5); slide 3, unamplified sample 3 
(Cy3) + unamplified sample 6 (Cy5); slide 4, amplified sample 1 (Cy5) + amplified 
sample 4 (Cy3); slide 5, amplified sample 2 (Cy5) + amplified sample 5 (Cy3); slide 6, 
amplified sample 3 (Cy5) + amplified sample 6 (Cy3). Arrays were hybridized and 
washed according to the manufacturer’s protocol and scanned by a laser scanner (GMS 
417’ MWG-Biotech). Computer-assisted data evaluation was performed with use of the 
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ArrayVision software (Imaging Research, Inc.) as described previously [3]. In brief, 
negative hybridization signals revealed intensity values <3000, the gray area range was 
3000–5000, and positive hybridization signals showed intensity values >5000. Mean 
values were calculated from the six unamplified and the six amplified samples for each 
gene spot on the microarray. The mean values from the unamplified and the amplified 
samples were compared in a scatter plot. 
 
RESULTS 
Platelet preparation and precision of RNA isolation 
Platelets were prepared from 40 mL of citrate-anticoagulated blood from 16 healthy 
volunteers. Platelet count ranged from 105 000 to 259 000/µL. Leukocyte counts ranged 
from 3600 to 6100/µL. After preparation of PRP and leukofiltration, no leukocytes were 
detectable by flow cytometric analysis. Mean (SD) platelet loss attributable to 
preparation of PRP and leukofiltration was 72 (3)%. To determine the precision of mRNA 
isolation with oligo(dT)-coupled magnetic beads, we aliquoted platelets obtained from 
one donor by platelet apheresis after filtration (1x1010 platelets each), and mRNA was 
extracted in triplicate on 3 different days. vWF and GAPDH mRNA was analyzed by 
quantitative RT-PCR. The mean (SD) the threshold cycle (Ct) values were 30.1 (0.65) 
and 19.1 (0.27) for vWF and GAPDH mRNA, respectively; the CVs indicate the low 
intraassay variation. For the run-to run-variation, the mean (SD) Ct values were 30.21 
(0.65) and 19.52 (0.45) for vWF-and GAPDH mRNA, respectively.  
 
Efficiency of amplification 
One of the most critical steps in PCR-based RNA amplification is the maintenance of the 
original message profile. To obtain optimum results, PCR should be in the exponential 
phase of the reaction, and irrespective of length and abundance, all mRNAs should be 
amplified with equal efficiency. To establish optimum PCR conditions, purified total 
platelet RNA at concentrations of 50 ng, 100 ng, and 1 µg was subjected to SMART-
PCR amplification. During the process of PCR amplification, aliquots were repeatedly 
taken from each sample, and the concentrations of vWF, F13A, and GAPDH cDNA were 
measured. Copy numbers exponentially increased from cycles 10 to 18 for all RNA 
species tested when 50 or 100 ng of initial RNA was used (Fig. 1). At a starting RNA 
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concentration of 1 µg, the reactions became nonexponential after 16 amplification cycles 
for F13A and GAPDH, whereas vWF amplification remained in the exponential phase. 
Interestingly, we failed to detect message for FGA in our samples. We confirmed this 
result by testing 10 additional unamplified and SMART-amplified platelet RNA samples 
from 10 healthy individuals who tested positive for vWF transcripts.  
The amplification efficiencies were calculated for each initial RNA concentration 
according to the formula: E = es - 1, where E is the efficiency of the PCR and s is the 
slope of the corresponding interpolation curve (Fig. 1). Efficiencies for vWF RNA 
amplification were 0.81, 0.84, and 0.80 when we used 50 ng, 100 ng, and 1 µg of total 
RNA, respectively, as the initial starting concentration. In contrast to the nearly identical 
amplification efficiencies observed for vWF, the 
amplification efficiencies of F13A (0.66, 0.65, and 
0.36) and GAPDH (0.72, 0.76, and 0.65) transcripts 
decreased with increasing concentrations of starting 
RNA (50 ng, 100 ng, and 1 µg). Overall, the 
amplification efficiency was higher for vWF 
amplification than for GAPDH or F13A amplification. 
 
 
 
 
 
Figure 1. Gene-specific monitoring of SMART 
amplification by quantitative real-time PCR. Total 
platelet RNA at concentrations of 0.05 µg (S), 0.1 µg (), 
and 1 µg () was amplified by the SMART method. At the 
indicated amplification cycle numbers (x axis), vWF (A), 
F13A (B), and GAPDH cDNA (C) concentrations were 
measured by quantitative real-time PCR. Results are shown 
as mean (SD; error bars) of three independent experiments. 
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Precision of amplification results 
The assay-to-assay variation, which defines the precision of the amplification process, 
was calculated by analysis of cDNAs generated from identical RNA samples (0.5 µg) 
using 14, 18, and 22 amplification cycles three times on 3 different days. The mean Ct 
values of the multiplex vWF/GAPDH PCR decreased with increasing SMART 
amplification cycles. The corresponding SD increased with increasing SMART 
amplification cycles, but they did not exceed 0.73 for both transcripts tested. Considering 
that these values include the intraassay variability of the PCR, they are remarkably low. 
We determined the intraassay variability of the multiplex PCR by processing each cDNA 
calibration dilution six times in one experiment. The maximum SD values calculated on 
the basis of Ct values were 0.19 and 0.23 for vWF and GAPDH, respectively. 
 
Gene expression profiles of unamplified and smart-amplified platelet rna  
The platelet gene expression profile was determined in six microarray hybridization 
experiments with either unamplified or SMART-amplified platelet RNA obtained from six 
single donor platelet concentrates. Mean hybridization signals were calculated for each 
gene and compared between the unamplified samples (directly labeled with Cy3 or Cy5 
by reverse transcription) and the amplified samples (SMART-amplified and labeled with 
Cy3 or Cy5). The scatter plot of mean signal intensity values of the unamplified vs the 
amplified samples revealed a strong linear relationship (R2 = 0.915; Fig. 2). Positive 
hybridization signals were detected for 1576 genes (16%) in all samples. The most 
prominent genes corresponded to those described previously [3], such as platelet factor 
4, RANTES, glycoprotein Ibβ, and others. For 8239 genes (83.6%), we found signal 
intensities in the gray area or negative range in all samples analyzed. The CVs were in 
the range of 0.001–1.6 [mean (SD), 0.34 (0.17)] for the unamplified samples and 0.001–
1.4 [0.31 (0.16)] for the amplified samples. The hypothetical protein KIA0433 revealed 
that the highest CV values were 1.6 in the unamplified and 1.4 in the amplified samples. 
This was attributable to the highly positive signal intensity values in unamplified and 
amplified RNA sample 5, whereas the signals were negative or in the gray area range in 
all other RNA samples. Similar results could be seen for the ribosomal protein L29 
(CVunamplified = 1.22; CVamplified = 1.39), the ubiquitin-specific protease 1 (1.26 and 1.12, 
respectively), the acid fibroblast growth factor-like protein GLIO703 (1.22 and 1.20, 
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respectively), and others. In summary, 10 genes had CV values >1 in both sample 
types. Furthermore, 28 genes had CV values >1 in at least one of the two sample types 
(25 genes only in the unamplified samples; 3 genes only in the amplified samples). In all 
cases, the high CV values resulted from one or two positive signals among the six 
analyzed RNA samples, indicating an interindividual difference in gene expression.  
 
Figure 2. Scatter plot of mean signal intensity values from comparative microarray analysis. 
Glass slide microarrays representing 9850 human genes were used to characterize the mRNA profile 
in human platelets. Mean values of hybridization signals were calculated from six individual 
experiments for each individual gene and compared between unamplified (x axis) and SMART-
amplified samples (y axis), indicated by gray circles in the scatter plot. The line indicates the linear 
relationship between the microarray hybridization results from unamplified and amplified samples (R2 
= 0.915) calculated by the equation: y = 0.8226x + 203.5. 
 
Only 35 of the 9850 genes (0.4%) revealed discrepant results when we compared 
signal intensities for the unamplified and the SMART-amplified samples. A full list of 
these genes is given in table 2. Among these genes we identified 27 with negative 
signals in the unamplified samples and unambiguously positive signals in the amplified 
samples, such as the matrix metalloproteinase 14, troponin C2, and others. This may 
reflect the higher sensitivity of the SMART amplification and may not be regarded as a 
“true” discrepant result. Positive signals in the unamplified samples but negative signals 
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in the SMART-amplified samples were found for eight genes, such as serine racemase, 
actin-binding LIM protein 1, and others. Microarray analysis without amplification 
revealed positive hybridization signals for these genes in all RNA samples, but the 
signals were negative when we used the amplification technique. These should be 
regarded as true discrepant results because the SMART technique in combination with 
microarray hybridization analysis failed to detect the gene transcripts. 
 
Table2 . Genes with discrepant results in microarray analysis of unamplified and amplified 
platelet RNA. 
Gene 
symbol 
Gene description 
Mean signal intensity 
± SD* 
unamplified  
Mean signal intensity 
± SD* 
amplified 
Negative in the unamplified but positive in the amplified samples   
NEUROD2 Neurogenic differentiation 2 2,407 ± 507 63,947 ± 939 
TNNC2 Troponin C2, fast 2,327 ± 722 57,109 ± 8,175 
HSPA2 Heat shock 70kd protein 2 2,783 ± 824 35,871 ± 14,445 
CDR1 Cerebellar degeneration-related protein (34kd) 2,300 ± 257 32,709 ± 12,089 
TNNI2 Troponin I, skeletal, fast 1,419 ± 375 32,256 ± 14,665 
GNAO1 G protein, alpha activating activity polypeptide O 2,959 ± 1,077 30,992 ± 16,214 
PAX2 Paired box protein 2, isoform e 2,316 ± 303 30,821 ± 16,343 
RPL10 Ribosomal protein L10 2,453 ± 316 30,150 ± 12,014 
TPH1 Timeless drosophila homolog 2,455 ± 434 29,111 ± 12,980 
KIAA0938 Hypothetical protein KIAA0938 2,682 ± 631 28,167 ± 19,529 
EMK1 ELKL motif kinase 1, isoform a 2,518 ± 399 27,703 ± 12,678 
FOSB Murine osteosarcoma viral oncogene FBJ, homolog b 2,631 ± 921 27,543 ± 18,342 
PRSS7 Serine protease 7 (enterokinase) 1,545 ± 642 26,230 ± 10,018 
MMP14 Matrix metalloproteinase 14 1,180 ± 190 24,490 ± 7,945 
PTPRF Protein tyrosine phosphatase, receptor type F  1,494 ± 591 24,453 ± 3,613 
KIF5C Kinesin family member 5c 1,272 ± 287 24,315 ± 12,943 
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Gene 
symbol 
Gene description 
Mean signal intensity 
± SD* 
unamplified  
Mean signal intensity 
± SD* 
amplified 
ABCC9 ATP-binding cassette, sub-family c, member 9 1,834 ± 231 23,766 ± 16,136 
GSCL Goosecoid-like 1,911 ± 294 23,429 ± 13,377 
FLJ23469 Hypothetical protein FLJ23469 1,394 ± 284 21,009 ± 10,010 
C21orf108 Chromosome 21 open reading frame 108;  1,932 ± 210 20,648 ± 14,880 
NFIL3 Nuclear factor, interleukin 3 regulated 1,755 ± 244 19,096 ± 10,226 
FLJ21213 Hypothetical protein FLJ21213 1,583 ± 156 19,054 ± 5,660 
HMMR Hyaluronan-mediated motility receptor, isoform a 1,332 ± 192 17,058 ± 9,371 
MTMR3 Myotubularin related protein 3 1,356 ± 455 15,399 ± 5,967 
ACP5 Tartrate resistant acid phosphatase 5 1,172 ± 167 12,074 ± 4,117 
TFG TRK-fused gene 1,072 ± 404 11,277 ± 5,096 
FLJ23412 Hypothetical protein FLJ23412 1,723 ± 239 11,261 ± 2,208 
Negative in amplified but positive in unamplified samples   
SRR Serine racemase 20,020 ± 11,132 2,169 ± 306 
PEMT Phosphatidylethanolamine n-methyltransferase 12,962 ± 8,004 1,095 ± 197 
ABLIM Actin-binding LIM protein 1, isoform S 19,958 ± 7,083 2,130 ± 548 
BM029 Uncharacterized bone marrow protein BM029 21,987 ± 14,091 896 ± 170 
FLJ10849 Hypothetical protein FLJ10849 12,825 ± 4,171 2,594 ± 1,102 
FLJ22347 Hypothetical protein FLJ22347 13,784 ± 5,514 2,114 ± 1,633 
PRO0593 Predicted protein of HQ0593 8,633 ± 3,603 1,864 ± 733 
KIAA0963 Hypothetical protein KIAA0963 21,292 ±12,600 1,753 ± 520 
*mean signal intensity and standard deviation (SD) of unamplified (direct labeling by reverse transcription) 
and SMART-amplified samples: <3,000, negative, 3,000 – 4,999 gray area, ≥5,000, positive; bold 
numbers indicate values in the positive range and negative values are given as plain numbers. 
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Minimum sample size  
The minimum sample size was defined as the volume of whole blood needed as starting 
material to produce more than 5 µg of platelet cDNA with detectable vWF transcripts by 
SMART PCR amplification using a maximum of 18 cycles. The minimum platelet number 
needed for RNA extraction and cDNA generation was first determined by testing 
different numbers of platelets obtained by platelet apheresis. When we started with 
2x106 platelets, GAPDH or vWF transcripts were not detectable by quantitative PCR 
even after 22 amplification cycles. When we increased the platelet number to 2x107, we 
obtained measurable GAPDH transcripts but vWF remained undetectable. At starting 
concentrations of 2x108 platelets or more, both marker transcripts became detectable in 
a platelet concentration-dependent manner. Because 2x108 platelets are equivalent to 
2–4 mL of whole blood, we started the evaluation of the minimum volume of whole blood 
with a minimum of 5 mL. However, because of losses of thrombocytes during sample 
preparation and leukofiltration, 40 mL of whole blood was required to achieve reliable 
and reproducible results with a mean yield of 25–30 µg of cDNA. Typical results 
obtained with blood samples from healthy volunteers (platelet counts, 143.000-          
398 000/µL) are listed in Table 3. 
 
Table 3. RNA amplification results for three exemplary blood samples. 
 
sample # 1 2 3 
Platelets/40 mL whole blood 6.12 x 109 11.76 x 109 8.16 x 109
Platelets after sample preparation 3.76 x 109 6.48 x 109 4.28 x 109
Amplified cDNA, µg 34 29 26 
vWF transcripts/µg cDNA 9 x 106 237 x 106 80 x 106
GAPDH transcripts/µg of cDNA 3000 x 106 3972 x 106 2738 x 106
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Inter- and intraindividual variability of vWF, F13A, and gapdh transcripts in 
platelets  
Blood samples (40 mL of whole blood) from three healthy volunteers were obtained 
weekly over a period of 3 weeks. Platelet counts in citrate-anticoagulated blood ranged 
from 138 000 to 146 000/µL, 159 000 to 169 000/µL, and 217 000 to 265 000/µL in 
individuals 1, 2, and 3, respectively. After mRNA isolation, vWF, GAPDH, and F13A 
were quantified by RT-PCR. The results (Fig. 3) demonstrated interindividual variations 
for all three transcripts with the lowest concentrations seen in individual 1. These 
differences remained stable over time, indicating a low intraindividual variability. 
 
Figure 3. Intra- and interindividual 
variability of platelet vWF, F13A, 
and GAPDH gene expression. 
Whole blood (40 mL) was drawn 
weekly over a period of 3 weeks 
from three healthy volunteers 
(circles, individual 1; triangles, 
individual 2; squares, individual 3). 
After preparation of mRNA, vWF 
(closed symbols), GAPDH (open 
symbols), and F13A transcripts 
(open symbols with shadows) were 
quantified by RT-PCR. Results are 
shown as copy numbers (vWF and 
GAPDH) or units (F13A). 
 
DISCUSSION 
Our aim was to establish a protocol that makes analysis of the platelet transcriptome 
applicable to single patients with suspected platelet disorders.  
Contaminating leukocytes are a potential problem in platelet RNA analysis 
because the content of mRNA in leukocytes is >10 000-fold higher than in platelets [22]. 
To overcome this problem, several techniques, including laser-assisted microdissection 
and manipulation, serial filtration, and antibody-mediated depletion of leukocytes by 
magnetic beads, have been used [2,3,22]. Filtration is the only technique that is used on 
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a routine basis [24,25], and filters adapted for the processing of small volumes of PRP 
are commercially available. Taking these advantages into account, we studied the 
efficiency of leukocyte filtration by flow cytometry analysis and determination of CD45 
and CD14 transcripts. After one filtration, leukocytes were not detectable by flow 
cytometry analysis, and negative array results were obtained for CD45 and CD14 
transcripts. These results support previously published data obtained on large volume 
preparations of platelets [3,26]. When we used a more sensitive quantitative RT-PCR 
approach, however, low concentrations of CD45 transcripts were detectable, indicating 
that the filtered PRP was not completely devoid of leukocytes. Analyzing the efficiency of 
leukocyte filtration, we found that one filtration step reduced the amount of CD45 
transcripts by three orders of magnitude, corresponding to a reduction in the 
leukocyte/platelet ratio from 1:2000 to 1:2 000 000. Adding more filtration steps did not 
significantly reduce the concentration of CD45 mRNA but led to additional platelet loss. 
On the basis of these results, we included one filtration step in our experimental 
protocol.  
The quality of the mRNA preparation is of critical importance when working with a 
tissue source that contains only minute amounts of mRNA. We used oligo(dT)-coupled 
magnetic beads, which directly bind platelet mRNA representing 1–3% of total RNA. To 
control our mRNA isolation procedure, we isolated mRNA at various time points from 
one subsampled platelet preparation. Subsequently, the numbers of vWF and GAPDH 
transcripts were measured. The SD for the Ct values never exceeded 0.73, 
demonstrating the high reproducibility and precision of this procedure.  
The use of an amplification procedure before gene expression analysis requires 
maintenance of the original message profile. In our microarray investigation, we 
compared mRNA profiles from 10 µg of unamplified and 0.5 µg of SMART-amplified 
platelet RNA and found that 91.5% of the gene expression information was maintained. 
A total of 508 genes revealed negative signals in the unamplified samples but were 
positive (27 genes) or in the gray area range (481 genes) in the SMART-amplified 
samples. These results may be regarded as indicative of the higher sensitivity of the 
SMART technique, but not as true discrepancies. However, we observed a false-
negative microarray result in the SMART-amplified samples for eight transcripts. 
Obviously, amplification of these transcripts failed for unknown reasons. Their lengths 
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varied between 1.0 and 6.8 kb; therefore, length can probably be ruled out as a main 
reason for the amplification failure. One can speculate that failure of template switching 
at the 5’ end might occur because of secondary structures in these transcripts. Such 
failures must be considered for future studies on individual mRNA profiling of platelet 
RNA.  
SMART amplification revealed consistent results when we compared microarray 
data from six individual experiments. The CV for the majority of genes (8913 of 9850; 
90.5%) was <0.5, and only 13 genes had CV values <1. Mean CV values did not differ 
between amplified and unamplified samples. This confirmed the maintenance of gene 
expression profiles after SMART amplification. The observed differences may not result 
from the amplification technique but may represent individually different gene expression 
patterns.  
Comparability of array results depends on the array format used [27]. The array 
results presented here are consistent with our previously published data obtained with 
an identical platform (MWG Biotech) [3]. When we compared our results with the data 
published by Gnatenko et al. [2] and McRedmond et al. [6],we had to consider that these 
results were generated with a different microarray platform (Affymetrix). Among the 50 
most abundant platelet transcripts identified by Gnatenko et al. [2] and McRedmond et 
al. [6], 25 are arrayed on both platforms. For 22 of these genes, we confirmed strongly 
positive hybridization signals. Only three genes gave discrepant results: one gave signal 
intensities in the gray area (cofilin 1, nonmuscle) and two in the negative range 
(progesterone receptor component and nonmuscle myosin light chain). 
Quantification of vWF, F13A, and GAPDH as marker transcripts to determine how 
accurately PCR-generated cDNA reflects the original platelet mRNA population revealed 
exponential amplification between cycles 10 and 18 for all transcripts when 50 or 100 ng 
of total platelet RNA was used as starting material. However, amplification efficiency 
was slightly higher for vWF than for F13A and GAPDH. Most likely, this is attributable to 
the more than 200-fold lower concentration of vWF transcripts compared with GAPDH 
transcripts in the starting mRNA, which led to the C0t effect [28,29]. The bias toward 
more efficient amplification of low-abundance transcripts during SMART amplification 
has already been described in other tissues [15,18]. However, when we compared 
platelet RNA with SMART-amplified RNA by microarray analysis, the correlation was 
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excellent. Presumably, the semiquantitative microarray method is not sensitive enough 
to detect such differences, which can be seen with quantitative real-time PCR [29]. 
Using quantitative PCR, we were not able to detect FGA transcripts in any of the 
amplified or unamplified samples tested. This is in contrast to recently published array 
data [5], but agrees well with data obtained by in situ hybridization and PCR testing [30]. 
Both sensitive techniques failed to demonstrate FGA mRNA in platelets or 
megakaryocytes. The reason for this discrepancy remains unknown, but it emphasizes 
that array results need to be validated by independent methods such as RT-PCR.  
The platelet count is regulated in a narrow range with minimal day-to-day 
individual variation [31]. At present, however, no data are available on intra- and 
interindividual variability in platelet gene expression. In prelimi-  nary experiments, we 
measured changes in vWF, F13A, and GAPDH mRNA concentrations over time in three 
healthy individuals. The interindividual differences in the expression of all three 
transcripts remained stable over 3 weeks, indicating that there is only minor 
intraindividual variation.  
 
In conclusion, the assessed protocol allows production of micrograms of platelet-specific 
cDNA from blood volumes as low as 40 mL. SMART amplification does not cause 
distortion of the gene expression profile as estimated by microarray analysis. Preliminary 
results on samples from three healthy volunteers indicated interindividual differences of 
platelet gene expression profiles that seemed to be consistent over time. Therefore, this 
protocol makes platelet RNA isolated from single patients available for gene expression 
studies that may detect target genes involved in the development of inherited 
megakaryocytic/platelet disorders. 
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ABSTRACT 
Dural arteriovenous fistulas (DAVFs) are direct artery-to-cerebral venous sinus shunts. 
Our recent finding of a significantly increased prevalence of factor V (FV) Leiden in 
patients with DAVFs prompted us to evaluate prothrombinG20210A, MTHFRC677T, ß-
fibrinogenG455A, PAI-1 4G/5G and FXIIIVal34Leu as additional risk factors for 
thrombophilia in 26 patients with DAVFs and a group of age- and gender-matched 
controls. There was no significantly increased prevalence of these risk factors in DAVF 
patients. We conclude that FV Leiden is of pathogenetic significance in the aetiology of a 
subgroup of DAVFs whereas the other thrombophilic risk factors are not likely to be 
involved. 
 
INTRODUCTION 
Dural arteriovenous fistulas (DAVFs) are direct arterytocerebral venous sinus shunts, 
the etiology of which remains controversial. Initially thought to be of congenital origin, 
more recent data emphasize the role of cerebral sinus thrombosis and elevated sinus 
pressure. It has been proposed that impaired venous outflow favors the development of 
indigenous dysplastic dural vessels within the sinus establishing a direct artery-to-sinus 
communication and causes opening of preexisting microarteriovenous fistulas in the 
sinus walls [5,9,11]. In addition, we recently reported a significantly increased 
prevalence of resistance to activated protein C and factor V (FV) Leiden in white patients 
with DAVFs [8],suggesting a link between thrombophilia and the development of DAVFs. 
Therefore, we extended the search for thrombophilic risk factors to 
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prothrombinG20210A, methylentetrahydrofolate reductase (MTHFR) C677T, ß-
fibrinogenG455A, plasminogen activator inhibitor-1 (PAI-1) 4G/5G and factor XIII (F 
XIII)Val34Leu in a case-control study.  
 
PATIENTS AND METHODS 
Patients 
We recruited 26 patients with DAVFs, seen in the Departments of Neurology and 
Neuroradiology, Alfried-Krupp-Hospital, for endovascular treatment between May 1997 
and January 2001,and 26 age- (± 1 years) and gender-matched healthy control subjects 
without any evidence of cerebrovascular or cardiac disease or venous thrombosis. All 
individuals gave their written informed consent to the study. There were 13 males and 
13 females in the patient and in the control group. Mean age was 57 ± 12 years in 
patients and 58 ± 12 years in controls. Smoking and estrogen intake as risk factors were 
equally distributed in each group. The DAVFs were located as follows: occipital (10), 
temporal (4), cerebellar tentorium (4), cerebral falx (1), orbita (1), carotid-cavernous 
sinus (2), transverse sinus (1) ,spinal (3). Data of the FV Leiden mutation have been 
previously reported for 22 of these patients [8]. 
 
Methods 
DNA from peripheral blood leukocytes was extracted using the QIAamp DNA Blood Mini 
Kit (Qiagen,Hilden,Germany) according to the manufacturer’s protocol. Factor V 
G1691A (FV Leiden) [3], prothrombinG20210A, MTHFRC677T [4] and ß 
fibrinogenG455A [15] were determined as previously described. FXIIIVal34Leu was 
analysed by allelic discrimination using the TaqMan technique. Oligonucleotide 
sequences were 5’-GAAGATGACCTGCCCACAGTG-3’ (forward-primer), 5’-ATGCT- 
CATACCTTGCAGGTTGA-3’ (reverse-primer), 5’-FAM-AGCTTCAGGGCTTGGTG-
CCC-TAMRA-3’ (wildtype-probe) and 5’-TET-TCAGGGCGTGGTGCCCC-TAMRA-3’ 
(mutation probe). Fluorescence intensities were measured using the sequence detection 
system 7700 (Perkin Elmer, Weiterstadt, Germany). PAI-1 4G/5G was investigated by 
restriction fragment length polymorphism using a mutant forward primer 5’-
CAGAGAGAGTCTGGCCACGTG-3’ and reverse primer 5’-TGTCTAG-
GACTTGGGACCAACAG-3’. Amplification products were digested with 1 U of Bsi I (New 
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England Biolabs,I nc. Beverly,MA,USA) and loaded on an ethidium-bromide stained 2% 
small DNA agarose-gel (Biozym,Hessisch Oldendorf,Germany).  
For statistical analysis,the Student’s t-test and the Fisher’s exact test were used. 
 
RESULTS 
The results of prothrombinG20210A, MTHFRC677T, ß-fibrinogenG455A, PAI-1 4G/5G, 
FXIIIVal34Leu are summarised in Table 1. The prevalence of homozygous and 
heterozygous alleles of the mutations or polymorphisms was not different between the 
DAVF patients and controls. Among the additional 4 DAVF patients not reported 
previously [8], one was heterozygous for the FV Leiden mutation, whereas the 4 
matching controls had wild-type FV. Thus, among the extended group of 26 DAVF 
patients analysed in the present and previous studies, 6 were heterozygous for the FV 
Leiden mutation (6/26; 23%). There was no preferred localisation of the DAVFs among 
the patients with FV Leiden compared with the DAVF patients with wild-type FV. Of the 
six DAVF patients with abnormal activated protein C resistance and heterozygosity for 
FV Leiden, two patients had a history of previous sinus thrombosis. In addition, there 
was another patient who had suffered from a deep leg vein thrombosis. Among the 
controls, no thrombotic events had occurred. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Genotype frequencies in DAVF 
patients and age- and gender-matched 
controls (n.s.: not significant). 
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DISCUSSION 
In this case-control study we did not find an association between prothrombin 
G20210A,MTHFRC677T, PAI1 4G/5G, ß-fibrinogenG455A, FXIIIVal34Leu and the 
presence of DAVFs. Thus, there is no evidence of a major pathogenetic role of these 
thrombophilic risk factors in the etiology of DAVFs. This contrasts our previous finding of 
a significantly increased prevalence of FV Leiden in DAVF patients confirmed in the 
present study. Among the investigated thrombophilic risk factors, FV Leiden exhibits the 
highest relative-risk for venous thrombosis [13] and is also known to play a considerable 
role in the development of cerebral venous thrombosis [10]. The prevalence of FV 
Leiden in patients with venous sinus thrombosis reported in the literature [10] is 
comparable to that found in our studies. This strongly supports the etiologic impact of 
cerebral venous thrombosis in the development of DAVFs. Compared with FV 
Leiden,the prothrombinG20210A-mutation has a lower relative risk for first venous 
thrombotic events and a relative risk 
for recurrent thromboembolic events similar to patients with a normal genotype [2,14]. In 
addition, compound heterozygotes (FV Leiden and prothrombinG20210A) may exhibit a 
further increase in the relative risk for these events. At present, the degree of an 
association between the prothrombinG20210A-mutation and cerebral venous 
thrombosis remains unclear [1,12]. It cannot be excluded that the number of DAVF 
patients studied here is too small to reveal a contribution of this mutation alone or as an 
additive risk factor. The polymorphisms of MTHFR, ß-fibrinogen, PAI-1 and FXIII 
are believed to contribute mainly to arterial thrombotic events [6,7], via elevated 
concentrations of homocysteine, fibrinogen, PAI-1 and an altered clot resistance to 
fibrinolysis. However, we did not find an association between these genetic variants and 
DAVFs. This would support the hypothesis that only thrombotic events of the venous, 
but not the arterial system may contribute to the development of DAVFs. This hypothesis 
demands further confirmation by additional prospective case control 
studies. In addition to the genetic factors investigated in this study, we previously ruled 
out a pathogenetic role of alterations of platelet counts, partial thromboplastin time, 
concentrations of fibrinogen, antithrombin III, protein S and cardiolipin-antibodies (IgG 
and IgM) in the development of DAVFs [8]. Taken together, this study corroborates our 
previous finding of a significantly increased prevalence of FV Leiden 
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in white patients with DAVFs,st rongly suggesting that FV Leiden is of pathogenetic 
significance at least in a subgroup of DAVFs. A major role of prothrombin G20210A, 
MTHFRC677T, ß-fibrinogenG455A, PAI-1 4G/5G and FXIIIVal34Leu in the 
pathogenesis of DAVFs was virtually ruled out. For clinical purposes, we conclude that 
thrombophilia screening in patients with DAVF can be restricted to FV Leiden. 
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Chapter 7 
 
Discussion 
 
The introduction of the real-time PCR in 1992 greatly improved the reliability and speed 
of nucleic acid detection. Monitoring of product accumulation in real-time provided 
insights into even the early kinetics of a PCR reaction, allowing more accurate product 
quantification than possible with conventional end-point methods. The increased speed 
of real-time PCR is due to the removal of post-PCR handling steps, as the detection of 
amplification-dependend fluorescence emission is performed in a ‘closed-tube’ format 
that also reduces the risk of false positive results stemming from contaminating 
amplification products. These advantages make the real-time PCR to the method of 
choice for a variety of applications, including the testing for pathogens, SNP analysis, 
and gene expression profiling. This thesis deals with the implementation of real-time 
PCR assays that have been developed for different purposes in the field of haemostasis 
and transfusion medicine. 
Human parvovirus B19 (B19) is an omnipresent and clinically significant pathogen. 
About half of 15-year-olds have specific anti-B19 antibodies [1]. Common manifestations 
of the infection are the mild febrile illness erythema infectiosum followed by acute 
arthropathy. Other severe manifestations include transient aplastic crisis and chronic 
anaemia in immunocompromised patients. Furthermore, infection during pregnancy is a 
major cause of fetal death [2]. Therefore, individual blood products given to patients that 
are exceptionally at risk in case of B19 infection should be free of infectious B19 
particles. 
Owing to its high sensitivity, the PCR is the method of choice for the screening of blood 
donors for B19 viruses by the detection of corresponding genome sequences. In the 
acute phase of B19 infection, however, virus can be present in the blood at 
concentrations >1012 copies/ml [3], giving the risk of contamination and subsequent false 
positive test results. This is in particular true if heterogenous PCR assays are used that 
necessitate the opening of reaction tubes for the post-PCR detection of cumulated 
amplification products.  
The real-time B19 PCR described in this thesis showed to be an excellent tool for the 
screening of blood donors for B19 genomes. Beside the advantages of the homogenous 
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assay format, also the implementation if a competitive internal control sequence was a 
significant improvement to previously described, heterogenous B19 PCR assays [4,5].  
Due to its quantitative characteristics, the described assay might also be applied to the 
testing of plasma donations scheduled for production pools. The contamination of 
plasma manufacturing pools with B19 DNA has been frequently described [6-8]. To 
reduce the load of B19 DNA in plasma-derived coagulation factor concentrates, it has 
been proposed that corresponding pools should not exceed levels of 104 IU/ml of B19 
DNA [9]. Reliable quantification of B19 DNA is a prerequisite in order to fulfil these 
requirements. In general, heterogenous PCR assays are limited due to the trade-off 
between sensitivity and the ability to provide quantitative test results [10]. In contrast, 
homogenous real-time PCR formats combine the advantages of high assay sensitivity 
with a broad dynamic range. Thus, they are more useful tools for the quantitative 
detection of viral genomes.  
Shortly after the introduction of the described B19 Real-time PCR assay, it has been 
found that the genetic diversity of B19 is higher than previously expected. Thus, B19 is 
now classified into genotypes 1 (former B19 isolates), 2, and 3 [11,12]. Recently, the 
contamination of coagulation factor concentrates with genotype 2 DNA has been 
reported. Although genotype 2 was not found to be a frequent contaminant, the authors 
stated that NAT methods should be optimised to ensure reliable detection of all 
genotypes of Parvovirus DNA in order to further improve the viral safety of blood-
products [13]. To assess the sensitivity of the described B19 Real-time PCR assay on 
genotype 2 and 3 templates, we performed multiple sequence alignments that showed 
that our assay might underestimate genotype 3 sequences. This disadvantage may be 
accepted for the screening of German blood donors since genotype 3 is currently mainly 
limited to France [11]. However, the prevalence of genotype 3 infection in Germany 
might increase as a result of travel and migration. Thus, continuous surveillance of 
Parvovirus variants is an important measure to estimate the risk of genotype 3 
transmission and the need for optimised NAT assays. 
Correct quantification of viral loads is generally challenged by sequence dissimilarities 
between different groups and subtypes of the virus of interest. For example, genome 
sequences within the different groups and subtypes of HIV-1 are much more distinct 
from each other than this is the case for the B19 genotypes [14]. In Europe, HIV-1 group 
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M subtype B is predominant, while non-group M infections are rare events. Thus, legal 
requirements for HIV-1 NAT screening procedures for blood products had been limited 
to the detection of all subtypes within group M of HIV-1 [15]. Recently, we described a 
HIV-1 group O infection in one of our blood donors that was not detected by our 
standard In-house HIV-1 real-time PCR assay [16].  
This case and the problematic nature of Parvovirus genotype 3 DNA mentioned above 
emphasize the challenge that generally underlies the development of probe-mediated 
real-time PCR procedures for the detection of viral genomes. By providing an additional 
sequence-specific hybridisation step, these assays are more specific than conventional 
single-round PCR methods. Furthermore, this feature enables the implementation of an 
internal control reaction to avoid false-negative results due to poor test performance or 
inhibition of amplification. In case of viral nucleic acid detection, however, conserved 
regions within different genome sequences have not only to be considered for the 
primers, but also for an additional fluorogenic probe. Since nucleotide mismatches 
between probe and target sequences have a high impact on the level of amplification 
dependent fluorescence generation, the design of oligonucleotides for the detection of 
viral genomes by real-time PCR is more pretentious.  
While obstructive for pathogen testing, the susceptibility of probe-mediated fluorescence 
generation to sequence variation is beneficial for genotyping purposes. In this thesis, the 
application of various 5’-nuclease assays for allelic discrimination have been applied for 
the analysis of thrombophilic risk factors in patients with dural arteriovenous fistuals 
(DAVFs). In addition to this relative small study, the described 5’-nuclease assays are 
frequently used for large scale routine testing in the scope of general diagnosis of 
thrombophilia. While quantitative homogenous PCR requires performance in real-time, 
fluorogenic amplification signals assayed for sequence specific discrimination are 
usually recorded in an end-point format as the valuation of these data is based merely 
on a qualitative survey. Therefore, amplification can be performed in conventional 
thermocyclers, markedly increasing throughput. The use of these ‘closed-tube’ assays 
dispenses with the need for post-PCR handling steps. Thus, the risk of inaccurate 
results caused by contamination or pipetting errors is markedly reduced in comparison 
to more labor-intensive conventional methods such as restriction fragment length 
polymorphism analysis or allele specific amplification. 
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Quantitative gene expression analysis is another application of real-time PCR described 
in this thesis. The general advantages of the homogenous assay format have already 
been mentioned above and are also significant for mRNA quantification purposes. 
Independent of the test system used, gene expression analysis is challenging since the 
original mRNA-profile in collected tissue or cell samples may rapidly alter by either 
unintended gene induction or mRNA degradation in vitro. Thus, reliable quantification of 
gene transcripts ex vivo requires accurate evaluation of preanalytical requirements. This 
prerequisite had to be considered with respect to the implementation of a test system for 
the quantitative detection of tissue factor transcripts in blood-monocytes.  
Tissue factor is known to be the main initiator of the coagulation cascade and may be 
expressed under certain conditions on intravascular cells. We were able to demonstrate 
that desmopressin acetate (DDAVP) is able to induce monocytic tissue factor gene 
expression in vivo. All blood samples taken during the DDAVP study were immediately 
processed in downstream applications. Thus, the question of optimal sample storage 
conditions was a minor one. However, especially if several hospitals or practices are 
involved in the collection of blood samples for TF gene expression analysis, the storage 
and transport of specimen prior isolation of total RNA becomes an important aspect. To 
ensure the preservation of the monocytic mRNA profile ex vivo, a commercially available 
blood sampling system that includes a RNA stabilizing additive in the blood collection 
tube was evaluated. The combination of this blood sampling system and the established 
real-time RT-PCR assay for quantification of TF-transcripts enabled TF gene expression 
rates to be determined in healthy blood donors under standardized conditions. This 
survey of a normal range of TF transcription rates provides an essential basis for further 
clinical studies on intravascular TF gene expression as a potential risk factor for venous 
thromboembolism (VTE). We recently described significantly increased levels of 
monocytic TF gene expression in outpatients with a history of VTE [17]. However, when 
compared to previously published data on monocytic TF gene expression in other 
pathologic situations, this is more of a moderate difference to our control group [18]. To  
further examine the role of TF gene expression in VTE, also more acute events have to 
be investigated. 
While single transcription rates are investigated primarily in the context of already 
clarified functions of the target gene, global gene expression profiling is studied to 
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understand which genes are generally involved in cellular processes under specific 
conditions. One limitation of microarray-based gene expression analysis is that a total of 
2-4 µg of total RNA is required for each experiment. Thus, low amounts of mRNA need 
to be amplified prior to microarray hybridisation. We described the evaluation of the so-
called ‘SMART’-method for global amplification of platelet cDNA. To ensure the 
preservation of the original mRNA profile, the characteristics of the performed 
amplification procedure had to be determined. The application of real-time PCR assays 
for absolute quantification of chosen marker transcripts permitted precise calculation of 
template-depended amplification efficiencies effected by the SMART procedure. These 
results were essential in determining the maximum number of amplification cycles 
possible while preserving the original mRNA profile of the platelet sample.  
Incoherent to the used global amplification procedure, there is evidence that gene 
expression analysis based on microarrays may lead to false positive results due to 
unspecific binding [19]. Recently, RNA coding for the fibrinogen alpha chain (FGA) has 
been detected in substantial amounts in human platelets using microarray analysis [20]. 
In contrast, we did not detect any FGA transcripts in different individual platelet 
preparations applying real-time PCR [21]. These data emphasize the need to validate 
individual genes expressed in microarray analysis by other independent methods like 
e.g. RT-PCR. To ensure maximal specificity, probe mediated real-time detection would 
be the method of choice. 
The homogenous 5’-nuclease assays described in this thesis are valuable methods, 
substantially enhancing the potential of molecular analysis in haemostasis and 
transfusion medicine. Compared to conventional methods, possible limitations are the 
potentially increased susceptibility to unpredicted sequence variations and the higher 
costs due to required probe chemistry and devices. In general, however, the ‘closed-
tube’ PCR format upgraded the field of molecular diagnosis and research in terms of 
reliability and speed. Pre-developed primer/probe sets for either quantitative expression 
analysis or single nucleotide polymorphism analysis are already commercially available 
in a genome-wide manner. Furthermore, Roche Diagnostics Corp. recently released the 
COBAS TaqMan analyzer, a real-time PCR instrument that was exclusively developed 
for the clinical laboratory. Based on this platform, certified analyte-specific reagents 
(ASR) for the quantification of e.g. viral genomes are already commercially available [22-
107 
24]. Thus, one can expect that real-time PCR applications will prospectively supplant 
conventional PCR assays currently in use.  
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Chapter 8 
 
Summary 
 
The introduction of the real-time PCR into the medical field significantly broadened the 
possibilities of both, diagnostics and research. Since first described in 1992, a variety of 
fluorogenic chemistry systems has been applied on different real-time PCR platforms. 
Due to the ‘closed tube’ format and the possibility to have insights into the entire kinetics 
of a PCR reaction, real-time PCR strongly improves the performance of nucleic acid 
detection regarding reliability and speed.   
This thesis deals with the development and application of novel real-time PCR assays in 
the field of haemostasis and transfusion medicine.  
Chapter 1 gives an general overview of real-time PCR and its current applications in 
haemotherapy. The development and validation of a real-time PCR assay for the 
detection of Parvovirus B19 DNA in blood donations is described in chapter 2. This 
sensitive and internal controlled PCR assay fulfils all criteria for the routine screening of 
predominantly B19 negative blood donations. A real-time PCR platform for the 
quantification of tissue factor (TF) mRNA in circulating blood monocytes is presented in 
chapter 3. To ensure reliable test results, a blood sampling system that includes a RNA 
stabilizing additive was evaluated. Utilizing the described TF real-time PCR assay we 
were able to demonstrate that desmopressin acetate (DDAVP) is able to induce 
monocytic tissue factor gene expression in vivo (chapter 4). By the application of 
different real-time PCR assays for absolute quantification of chosen marker transcripts, it 
was possible to validate the so-called SMART procedure for global amplification of 
platelet mRNA sequences applied for subsequent gene expression analysis (chapter 5). 
As described in chapter 6, different 5’-nuclease assays were used for the allelic 
discrimination of thrombophilic risk factors in patients with dural arteriovenous fistuals 
(DAVFs). 
In summary, the real-time 5’-nuclease assays described in this thesis showed to be 
valuable methods that strongly improved the possibilities of molecular analysis in 
haemostasis and transfusion medicine. Generally, real-time PCR applications will 
continuously compensate for conventional PCR assays currently in use. However, this 
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process will most probably be based on pre-developed assay formats that are already 
available in a genome-wide manner. 
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Zusammenfassung 
 
Die 1985 von Mullis et al. erstmals beschriebene Methode der Polymerase 
Kettenreaktion (Engl.: Polymerase Chain Reaction, PCR) hat die Arbeit molekular-
genetisch ausgerichteter Laboratorien grundlegend verändert. Mit der PCR ist es 
möglich, eindeutig definierte Abschnitte eines DNA-Strangs in-vitro ohne die Beteiligung 
von Mikroorganismen zu vervielfältigen. Die PCR wird heute in allen biologischen und 
medizinischen Laboratorien für eine Vielzahl verschiedener Anwendungen eingesetzt. 
Eine Weiterentwicklung der konventionellen PCR-Methode stellt die 1992 von Higuchi et 
al. entwickelte Echtzeit-Detektion der exponentiell verlaufenden Produktakkumulation 
dar. Die Anwendung von Echtzeit-PCR-Verfahren (Engl.: Real-time PCR) erlaubt eine, 
im Vergleich zu End-Punkt-Methoden, zuverlässigere Quantifizierung des 
Ausgangsmaterials über einen weiten Konzentrationsbereich. Ein weiterer Vorteil der 
Real-time PCR ist die Detektion der amplifikationsbedingten Fluoreszenzgenerierung im 
geschlossenen System, was die Gefahr einer Kontaminationen mit verschleppten PCR-
Produkten erheblich reduziert und durch den Wegfall konventioneller 
Detektionsmethoden auch einen erheblichen Zeitvorteil mit sich bringt. 
Die ursprüngliche und auch am weitesten verbreitete Real-time PCR Methode basiert 
auf der Zugabe eines Fluoreszenzfarbstoffes (z.B. SYBR Green I ®), dessen 
spezifisches Emmisionssignal nach Einlagerung in die doppelsträngigen PCR-Produkte 
ein Maximum erreicht. Des weiteren wurden über die Zeit verschiedenste 
fluoreszenzmarkierte Sondensysteme entwickelt, welche erst nach spezifischer 
Hybridisierung an einen der beiden Stränge der PCR-Produkte zur 
Fluoreszenzgenerierung führen. Durch die Verwendung verschiedener 
Fluoreszenzfarbstoffe eröffnen diese sequenz-spezifischen Real-time PCR Methoden 
ebenfalls die Möglichkeit der Detektion verschiedener PCR-Produkte in einem multiplen 
Reaktionsansatz. 
In der vorliegenden Arbeit wird die Entwicklung und Anwendung verschiedener Real-
time PCR Verfahren im Bereich der Hämostaseologie und Transfusionsmedizin 
beschrieben. Die auf dem 5’-Exonuklease Prinzip (Hydrolisierungssonden) basierten 
Applikationen wurden zur Quantifizierung von Nukleinsäuren oder der Diskriminierung 
klinisch relevanter Polymorphismen/Mutationen etabliert und bildeten die Grundlage der 
in den einzelnen Kapiteln dieser Arbeit dargestellten Ergebnisse.  
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Die in Kapitel 2 beschriebene Real-time PCR Methode zur quantitativen Detektion von 
Parvovirus B19 (B19) DNA erfüllt alle Voraussetzungen zur routinemäßigen Testung von 
Blutspendern und liefert somit einen wichtigen Beitrag zur Sicherheit von Blutprodukten 
und Faktorenkonzentraten. Der zur Amplifikation ausgewählte Bereich des Parvovirus 
Genoms ist hochkonserviert und sichert somit zumindest die Erfassung verschiedener 
Isolate der dominanten Genotypen 1 und 2. Die bei jeder Isolation der Nukleinsäuren 
und anschließenden Amplifikationsreaktion mitgeführte interne Kontrollsequenz 
überprüft jeden dieser Schritte hinsichtlich deren Effektivität und verhindert somit falsch 
negative Testergebnisse. Aufgrund der beschriebenen quantitativen Eigenschaften des 
Testsystems ist es möglich, B19 positive Einzelspenden mit niedriger Viruslast zu 
identifizieren, deren entsprechend potenziell hoher Gehalt an B19 Antikörpern zur 
Produktsicherheit von aus Poolplasma hergestellten Faktorenkonzentraten beitragen 
kann.  
Während die zuverlässige Detektion viraler Nukleinsäuren in erster Linie von der 
Verfügbarkeit entsprechend konservierter Genombereiche abhängig ist, ist im Rahmen 
von Untersuchungen zur Gen-Expression verstärkte Aufmerksamkeit den 
präanalytischen Einflussfaktoren zu widmen. Diesem Umstand wurde bei der 
Entwicklung des in Kapitel 3 beschriebenen Testsystems zur absoluten Quantifizierung 
monozytärer Tissue Factor (TF) mRNA in Vollblut durch Verwendung eines 
kommerziellen RNA-Stabilisatorsystems Rechnung getragen. Mit der ebenfalls in Kapitel 
3 beschriebenen TF Real-time PCR Methode konnte bereits im Vorfeld der Etablierung 
des RNA-Stabilisatorsystems ein die monozytäre TF-Gen-Expression induzierender in-
vivo Mechanismus von Desmopressin-Acetat (DDAVP) nachgewiesen werden (Kapitel 
4). Da alle in dieser Studie gewonnenen Blutproben unverzüglich analysiert werden 
konnten, stellte sich die Problematik präanalytischer Einflussfaktoren in diesem Fall 
nicht unmittelbar. Zukünftig geplante, multizentrische Studien mit Fragestellung der 
Rolle der monozytären TF-Gen-Expression im Kontext venöser Thromboembolien 
allerdings verlangen nach einer adäquaten Stabilisierung des monozytären mRNA-
Profils ex vivo. Auch die Erhebung eines entsprechenden Referenzwertbereiches unter 
standardisierten Bedingungen muss einer solchen Studie vorangestellt werden. Beidem 
wurde mit den in Kapitel 3 dargestellten Ergebnissen entsprochen. 
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Im Gegensatz zu der zielgerichteten Analyse der Expression bestimmter Gene im 
Rahmen einer bestimmten Fragestellung finden Genchips (Engl.: Microarrays) 
Anwendung bei der Untersuchung globaler Gen-Expressionsmuster. Ein Nachteil der 
Microarray-Technologie ist die im Vergleich zu Real-time PCR-Verfahren höhere Menge 
an benötigtem Ausgangsmaterial von 2-4µg an totaler RNA. Aus diesem Grund muss in 
Fällen, bei denen nur eine geringe Menge an zu untersuchender RNA zur Verfügung 
steht, eine globale mRNA-Amplifikation der eigentlichen Microarray-Analyse 
vorangestellt werden. Kapitel 5 dieser Arbeit beschreibt die Evaluierung der sog. 
SMART-Methodik bezüglich der globalen Amplifikation revers-transkribierter mRNA zur 
globalen Gen-Expressionsanalyse individueller Thrombozytenpräparationen. Mit Hilfe 
der beschriebenen Real-time PCR Verfahren war es möglich, ausgewählte Transkripte 
über den globalen Amplifikationsvorgang hinweg zu quantifizieren, um 
Rahmenbedingungen zu definieren, welche den Erhalt des ursprünglich vorhandenen 
mRNA-Profils sicherstellen. 
In Kapitel 6 wird die Anwendung verschiedener homogener PCR-Verfahren zur Allel-
spezifischen Diskriminierung genetisch determinierter, thrombophiler Risikofaktoren 
beschrieben. Der wesentliche Vorteil im Vergleich zu konventionell durchgeführten 
Methoden besteht hier wiederum in dem Wegfall nachgeschalteter Diskriminierungs-
bzw. Detektions-Methoden, was den Probendurchsatz erhöht und die Gefahr von 
potentiellen Kontaminationen oder Verwechslungen reduziert. 
 
Zusammenfassend belegen die in dieser Arbeit beschriebenen, neu entwickelten Real-
time PCR Applikationen für die Indikationsgebiete Hämostaseologie und 
Transfusionsmedizin das breite Spektrum der Einsatzmöglichkeit dieser Methodik, das 
vom Mutationsscreening über die Infektionsdiagnostik bis zur Genexpressionsanalyse 
reicht. Mögliche Limitierungen dieser Methodik stellen die im Vergleich zu 
konventionellen PCR Verfahren erhöhte Anfälligkeit bezüglich viraler 
Sequenzvariationen und die durch die benötigen Gerätschaften und zusätzlich 
verwendeten Oligonukleotide verursachten Mehrkosten dar.  
Schon heute werden von mehreren Herstellern Primer/Sonden-Sets zur genomweiten 
Gen-Expressionsanalyse bzw. SNP-Detektion angeboten. Des weiteren wird auch das 
Angebot komplett zertifizierter Testsysteme, wie sie beispielsweise in der molekularen 
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Infektionsdiagnostik eingesetzt werden, bezüglich homogener PCR-Verfahren immer 
umfangreicher. Aus diesem Grund ist davon auszugehen, dass zukünftig homogene 
PCR-Formate konventionelle Anwendungen mehr und mehr ersetzen werden.  
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